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INTRODUCTION
Tuberculosis (TB) is as old as the mankind. TB is the most common cause of death 
due to a single infectious agent worldwide in adults. According to the recent estimates, one 
third  of  the  human  population  (2  billion  people)  is  infected  with  Mycobacterium 
tuberculosis worldwide1. Of these, more than half the cases occur in five South-East Asian 
countries. India accounts for nearly one third of the global TB burden. In 2007, nearly 1.77 
million people died of TB and the global case fatality rate is estimated to be 45% in HIV-
positive  TB-patients  and 35% in  HIV-negative  TB-patients.  Nearly 500,000 people  die 
from TB in India every year — more than 1,000 every day, 1 every minute2
The  disease  though  known  since  ancient  times,  the  organism  causing  TB  was 
described only a century ago by Robert Koch on 24th March 1882. Until middle of the 20th 
century,  there  was  no  definitive  treatment  available  for  TB.  With  the  availability  of 
Streptomycin, Isoniazid and Para aminosalicylic acid (PAS), in the mid 1940s, predictable, 
curative treatment for TB became a reality. The introduction of Rifampicin, Pyrazinamide 
and  Ethambutol  in  the  subsequent  years  ushered  in  the  era  of  short-course  treatment. 
Further, the fully supervised sanatorium based treatment of the earlier days also gave way 
to the totally unsupervised domiciliary treatment. Soon, it was felt that TB could be easily 
contained  and  possibly  eradicated.  The  advent  of  HIV  infection,  the  acquired 
immunodeficiency  syndrome  (AIDS)  pandemic  in  the  1980s,  struck  a  blow  to  this 
optimism and there has been a global resurgence of TB especially the multi drug resistant 
strains. .The rise in tuberculosis (TB) incidence over the last two decades is TB deaths in
HIV-infected patients and partly due to the emergence of multidrug resistant strains of the 
bacteria3.
Multidrug-resistant tuberculosis (MDR-TB) is among the most worrisome elements 
of the pandemic of antibiotic resistance because TB patients that fail treatment have a high 
risk of death4.
Though studies published from the developing world suggested that drug resistance 
was a potential problem, it was the emergence of MDR-TB in USA in the 1990s which 
attracted the attention. A review by WHO of a series of 63 surveys of drug resistant TB 
carried out between 1985 and1994 led to the conclusion that the problem of drug resistance 
was global. The WHO, for the first time, introduced the term MDR ‘hotspot’ where high 
prevalence  of  MDR had been observed.  The ‘hotspot’  referred  to  countries  or  regions 
where the combined prevalence of MDR TB exceeded 5%5.According to a WHO data from 
81  countries  and  91,577  patients  collected  between  2002-2006  shows  MDR-TB,  on 
average, in 5.3% of all TB cases 6
In  India,  prevalence  of  primary  MDR-TB  in  newly  diagnosed  cases  has  been 
observed  to  be  3.4  per  cent  or  less.  Data  meticulously  collected  at  the  Tuberculosis 
Research Centre (TRC), Chennai over the last three decades suggest that MDR-TB levels 
in  newly  diagnosed  patients  have  been  one  per  cent  or  less7.  Prevalence  of  MDR-TB 
among previously treated patients has been observed to be higher. 
In view of the emerging resistant mutants in the global and Indian scenario, the 
need for prompt detection of Mycobacterium tuberculosis in suspected cases, susceptibility 
pattern  and  genetic  basis  of  drug  resistance  becomes  paramount  importance.  In  most 
laboratories  in  developing  countries,  smear  examination  and  culture  remains  the  only 
available choice. Though culture is the gold standard, it is time consuming due to the long 
replication time of mycobacteria and results are available only by 4-8 weeks. 
Good, reliable laboratory support is seldom available in developing nations. When 
facilities for culture and sensitivity testing are not available, therapeutic decisions are most 
often made by Standard Guidelines such as those published by the WHO.
Although the DOTS strategy is the basis of good TB control, the strategy should be 
modified  in  some  settings  to  identify  drug-resistant  cases  sooner,  and  to  make  use  of 
second-line drugs in appropriate treatment regimens8.
% of MDR-TB among new TB cases 1994-2007
Ref: http://www.who.int/tb/features_archive/drs_factsheet.pdf
_                       Aims  &  Objectives  
AIM
• To detect multidrug resistance in Mycobacterium tuberculosis 
OBJECTIVES
• Isolation and characterization of Mycobacterium tuberculosis in respiratory specimens 
collected from patients attending the RNTCP outpatient clinic and from inpatients at 
PSG Hospitals by conventional methods. 
• To detect  drug resistance  for Isoniazid  and Rifampicin  by two phenotypic  methods 
namely Absolute concentration method  and MTT assay 
• To  detect  mutations  in  rpoB  gene  from the  above  Rifampicin  resistant  isolates  of 
Mycobacterium tuberculosis by genotypic method using PCR and DNA Sequencing 
                 _  Review of Literature  
LITERATURE REVIEW
Tuberculosis in India is one of the largest public health problems of immense consequence, 
with an estimated one death per minute2. Tuberculosis (TB) has been declared as a global 
health emergency by the World Health Organization (WHO). This has been mainly due to 
the emergence of multiple drug resistant strains and the synergy between tubercle bacilli 
and the human immunodeficiency virus (HIV)8
History9
Tuberculosis is a disease of great antiquity and has almost certainly caused more suffering 
and death than any other infection.  The clinical  features  of both respiratory and spinal 
tuberculosis were well described by Hippocrates in about 4000 BC; accounts of the disease 
appeared in the Vedas and other ancient Hindu texts, in which it was termed rajayakshma – 
the king of diseases – and it afflicted Neolithic and pre-Columbian Ameridians.
The  transmissible  nature  of  tuberculosis  was  established  by  Villemin  in  1868  by 
inoculating  rabbits  with  tuberculous  material  from  humans  and  cattle.  Villemin  also 
established  that  scrofula  (tuberculous  lymphadenitis)  and  pulmonary  tuberculosis  were 
manifestations of the same disease process. In 1882 Robert Koch succeeded in cultivating 
the bacillus on inspissated serum and transmitted the disease to many animals of different 
species  by inoculating  with pure cultures  of  the bacillus.  In addition  to  cultivating  the 
organism,  Koch  succeeded  in  staining  it  by  treatment  with  an  alkaline  solution  of 
methylene blue for 24 hrs. Subsequently Ehrlich improved the technique by using a hot 
solution of carbol fuchsin and it is this technique modified by Ziehl and Neelsen that is 
widely used today.
General Characteristics9
Tuberculosis in humans was shown to be caused by two types of bacillus – human and the 
bovine  types  designated  as  Mycobacterium  tuberculosis and  Mycobacterium  bovis 
respectively. The mycobacterium tuberculosis complex includes  M.tuberculosis, M.bovis,  
M.africanum, M.microti and M.canettii.
The other environmental mycobacteria recognised as causative agents of human disease 
were called as non tuberculous mycobacteria (NTM) or Mycobacteria other than tubercle 
bacilli (MOTT)
Mycobacterium tuberculosis.
M.  tuberculosis is  the  most  common  pathogenic mycobacterial  species  in  the 
M.tuberculosis complex
Scientific classification
Kingdom    : Bacteria
Phylum      : Actinobacteria
Order         : Actinomycetales
Suborder    : Corynebacterineae
Family        : Mycobacteriaceae
Genus        : Mycobacterium
Species      :  tuberculosis
Habitat 
Mycobacterium species are isolated from a wide variety of environmental sources 
including water, soil, dust and Sphagnum vegetation. Mycobacteria have been classified as 
pathogens, or free living saprophytes. Obligate pathogens are species that do not appear to 
multiply outside their hosts and include  M.tuberculosis complex,  Mycobacterium leprae,  
Mycobacterium marinum,  and Mycobacterium  paratuberculosis. Tuberculosis  manifests 
both as pulmonary and extra pulmonary in humans and warm blooded animals and has 
become a new threat in developing countries in the most recent past10.
Morphology
M. tuberculosis is a straight or slightly curved rod, about 3µm x 0.3 µm, occurring 
singly, in pairs or as small clumps. The size depends on conditions of growth, and long 
filamentous,  club shaped and branching forms may be sometimes seen.  Mycobacterium 
bovis is usually straighter, shorter and stouter.
Tubercle bacilli have been described as Gram positive, though strictly speaking this 
is not correct, as after staining with basic dyes they resist decolourisation by alcohol even 
without the mordanting effect of iodine. When stained with carbol fuchsin by the Ziehl-
Neelsen  method  or  by  fluorescent  dyes  (auramine  O,  rhodamine),  they  resist 
decolourisation by 20 percent sulphuric acid and absolute alcohol. This acid and alcohol 
fastness has been ascribed variously to the presence in the bacillus of an unsaponifiable 
wax  (mycoloic  acid)  or  to  a  semipermeable  membrane  around  the  cell.  Electron 
micrographs  of thin sections  show that  the thick cell  wall  is  composed of three layers 
enclosing a trilaminar plasma membrane.
Cultural Characteristics11
The bacilli grow slowly, the generation time in vitro being 14-15 hours. Colonies 
appear  in  about  two  weeks  and  may  sometimes  take  up  to  eight  weeks.  Optimum 
temperature is 37ºC and Optimum pH is 6.4-7.0.  M. tuberculosis is an obligate aerobe. It 
grows luxuriantly in culture as compared to  Mycobacterium bovis which grows sparsely. 
They are  termed  as  eugenic  and dysgenic  respectively.  The  addition  of  0.5% glycerol 
improves the growth of M.tuberculosis.
Tubercle  bacilli  do  not  have  exacting  growth  requirements  but  are  highly 
susceptible even to traces of toxic substances like fatty acids in culture media. The toxicity 
is neutralized by serum albumin (or) charcoal. Koch originally grew the bacillus on heat 
coagulated bovine serum. Several media, both solid and liquid media have been described 
for the cultivation of tubercle bacilli.  The solid media contain egg (Lowenstein-Jensen, 
Petragnini, Dorset),  Blood (Tarshis), serum (Loeffler) or potato (Pawlowsky).  The solid 
medium most  widely  employed  for  routine  culture  is  Lowenstein-Jensen (LJ)  medium 
without starch, as recommended by the International Union Against Tuberculosis (IUAT). 
Among the several liquid media described, Dubo’s, Middle brook’s, Proskauer and beck’s, 
Sula’s and Sauton’s media are the more common.
On solid media,  M.tuberculosis forms dry, rough, raised, irregular colonies with a 
wrinkled surface. They are creamy white, becoming buff coloured on further incubation. 
In liquid media without dispersing agents the growth begins at the bottom, creeps up the 
sides and forms a prominent surface pellicle which may extended along the sides above the 
medium.
Identification of Bacteria
Once an  isolate  has  been recovered  in  the  mycobacteriology laboratory,  certain 
characteristics may be used to classify the isolate before performing biochemical tests.
         The first step is to confirm that the isolate recovered in broth or solid media culture is  
an  acid-fast  organism  by  performing  an  acid-fast  stain.  Then  once  the  organisms  are 
growing on solid  media,  phenotypic  characteristics  such as colony morphology,  growth 
rate,  optimum temperature  and  photo  reactivity  helps  to  speciate  Mycobacteria.  These 
characteristic do not allow for definitive identification but are presumptive and help in the 
selection of others, more definitive tests.
Colony Morphology
Colonies of Mycobacteria are generally distinguished as having either a smooth and 
soft or a rough and friable appearance. Colonies of M. tuberculosis that are rough often also 
exhibit  a  prominent  patterned  texture  in  liquid  cultures  referred  to  as  cording  (curved 
strands of bacilli)
Growth Rate
Growth rate and recovery time depend on the species of Mycobacteria but are also 
influenced  by  media,  the  incubation  temperature,  and  the  initial  inoculum  size. 
Mycobacteria are generally categorized as having visible growth within or more than 7 
days. Rapid growers are able to produce colonies in fewer than 7 days.
Temperature
The optimum temperature and range at which a Mycobacterial species may grow 
may  be  extremely  narrow,  especially  at  the  time  of  initial  incubation.  The  growth  of 
M.tuberculosis occurs at 37 °C.
Photo-reactivity
Mycobacterium  species  have  traditionally  been  categorized  in  three  groups 
according to their photo reactivity characteristics. 
Photochromogens - that produce carotene pigment upon exposure to light (color ranges 
from pale yellow to orange).
Scotochomogens - that produce pigment in the light or the dark.
Non  Chromogenic  Or  Nonphotochromogenic-  colonies  are  buff  colored  and  are 
nonphotoreactive i.e. on exposure to light does not produce pigment e.g., M. Tuberculosis11
Biochemical Identification12
A panel of biochemical tests is available for the identification of Mycobacterium 
species.  Because  Mycobacterium  species  may  show  only  quantitative  differences  in 
enzymes used in biochemical identification, no single biochemical test should be relied on 
for the identification of a species, for expediency, all necessary biochemical tests should be 
set up at one time.
1. Niacin test:-
Most  Mycobacteria  possess  the  enzyme  that  converts  free  niacin  to  niacin 
ribonucleotide. Accumulation of niacin detected as nicotinic acid, is the most commonly 
used biochemical test for the identification of  M. tuberculosis. Nicotinic acid reacts with 
cyanogen bromide in the presence of an amine to form a yellow-pigmented compound. 
This test is positive with M.tuberculosis and negative with M. bovis.
2. Neutral red test:-
Virulent strains of tubercle bacilli  are able to bind neutral red in alkaline buffer 
solution, while avirulent strains are unable to do so 
3. Catalase-peroxidase test:-
Catalase is an intracellular enzyme that can split hydrogen peroxidase into water 
and oxygen. Catalase in atypical mycobacteria is stable when heated in a suspension to 
68ºC  while  M.tuberculosis loses  their  catalase  activity.  These  help  in  differentiating 
tubercle bacilli from atypical Mycobacteria and provide an indication of the sensitivity of 
the strains to isoniazid. On the other hand, tubercle bacilli are peroxidase positive, but not 
atypical  Mycobacteria.  Catalase  and peroxidase activities  are  lost  when tubercle  bacilli 
become Isoniazid resistant.
4. Nitrate reduction test:-
 The production of nitroreductase, which catalyzes the reduction of nitrate to nitrite, 
a red color forms by the addition of sulfanilamide and N- naphthylediamine to bacterial 
suspension incubated in nitrate  broth. This is positive with  M.tuberculosis and negative 
with M.bovis.
5. Growth in the presence of p-nitrobenzoic acid:-
This  compound  inhibits  the  growth  M.tuberculosis complex  namely  M. 
tuberculosis, M.bovis,  M.africanum  and  M.microti while  atypical  mycobacteria  are 
resistant and grow well in LJ containing PNB
6. Pyrazinamidase test:-
Pyrazinamidase is an enzyme that hydrolyzes  pyrazinamidase to pyrazinoic acid 
and ammonia. Ferrous ammonium sulfate combines with pyrazinoic acid producing a red 
pigment.  This  reaction  occurs  in  about  four  days  and may be  useful  in  distinguishing 
Mycobacterium bovis from M.tuberculosis and M. marinum from M. kansasi 
7. Growth in the presence of thiophen-2-carboxylic acid hydrazide:-
This test is useful to distinguish M.tuberculosis, which grows in the presence of this 
compound from other members of the M. tuberculosis complex
PATHOGENESIS
Mode of transmission
M.  tuberculosis is  most  commonly  transmitted  from  a  patient  with  infectious 
pulmonary  tuberculosis  to  other  persons  by  droplet  nuclei,  which  are  aerosolized  by 
coughing, sneezing, or speaking.
Signs and symptoms
 Fever and sweating
 Weight loss
 hemoptysis
 Dyspnea
 Thoracic pain
 Hoarseness
 Hepatosplenomegaly, in case of disseminated forms.
Clinical Manifestations 
 Tuberculosis is classified as pulmonary or extrapulmonary. Before the recognition 
of HIV infection, 80% of all cases of tuberculosis were limited to the lungs. However, up to 
two thirds of HIV-infected patients with tuberculosis may have either pulmonary and extra 
pulmonary disease or extra pulmonary disease alone.
Pulmonary Tuberculosis 
Pulmonary tuberculosis can be categorized as primary or post primary (secondary).
Primary Disease
Primary  pulmonary  tuberculosis  results  from  an  initial  infection  with  tubercle 
bacilli localized to the middle and lower lung zones. 
In the majority of cases, the lesion heals spontaneously and may later be evident as 
a small calcified nodule (Ghon lesion). In children and in persons with impaired immunity 
(e.g.,  those  with  malnutrition  or  HIV  infection),  primary  pulmonary  tuberculosis  may 
progress rapidly to clinical illness. The initial lesion increases in size and can evolve in 
different ways. In severe cases, the primary site rapidly enlarges, undergoes necrosis, and 
acute  cavitation  develops  (progressive  primary  tuberculosis).  Enlarged  lymph  nodes  of 
hilum  and  mediastinum  may  compress  bronchi,  causing  obstruction  and  subsequent 
segmental  or lobar collapse.  Partial  obstruction may cause obstructive emphysema,  and 
bronchiectasis. Hematogenous dissemination, which is common and is often asymptomatic, 
may  result  in  the  most  severe  manifestations  of  primary  M.  tuberculosis infection. 
Although healing frequently takes place, immunocompromised persons (e.g., patients with 
HIV infection) may develop miliary tuberculosis and/or tuberculous meningitis.
Post Primary Disease
Post primary disease also called adult-type, reactivation, or secondary tuberculosis, 
results  from endogenous  reactivation  of  latent  infection  and is  usually  localized  to  the 
apical  and posterior  segments  of the upper lobes,  where the high oxygen concentration 
favours  Mycobacterial  growth.  With  cavity  formation,  liquefied  necrotic  contents  are 
ultimately discharged into the airways, resulting in satellite lesions within the lungs that 
may in turn undergo cavitation.  Massive  involvement  of  pulmonary  segments  or  lobes 
produces tuberculous pneumonia.  One-third of untreated patients reportedly succumb to 
severe pulmonary tuberculosis within a few weeks or months after onset.
Physical findings are of limited use in pulmonary tuberculosis. Many patients have 
no abnormalities detectable by chest examination, while others have detectable rales in the 
involved  areas  during  inspiration,  especially  after  coughing.   The  most  common 
hematologic findings are mild anaemia and leukocytosis
Extra Pulmonary Tuberculosis
Tuberculosis  can  involve  any  organ  system  in  the  body.  While  pulmonary 
tuberculosis is the most common presentation, extra pulmonary tuberculosis (EPTB) is also 
an  important  clinical  problem.  The  term  EPTB  has  been  used  to  describe  isolated 
occurrence of tuberculosis at body sites other than the lung13
Different  forms  of  extra  pulmonary  tuberculosis  includes  miliary  tuberculosis, 
neurological  tuberculosis,  lymph  node  tuberculosis,  tuberculosis  pleural  effusion, 
abdominal tuberculosis, genitourinary tuberculosis, ocular tuberculosis, renal tuberculosis, 
pericardial tuberculosis, pancreatitis, otitis, bone and joint tuberculosis,.
TREATMENT
The treatment of tuberculosis (TB) has witnessed many important changes over the 
years. With the advent of effective antimycobacterial chemotherapeutic agents in the early 
1950s, the two main biological obstacles to successful treatment of TB were the high rate 
of  failure  during  treatment  and  the  high  risk  of  relapse  after  treatment.  With  the 
introduction of Rifampicin the outlook for treatment of TB changed dramatically. Today’s 
standard  regimen  directly  observed  therapy  short  course  (DOTS)  according  to  the 
WHO/IUATLD consists of a combination of three or four drugs (Isoniazid, Rifampicin, 
Ethambutol, Pyrazinamide) for two months followed by a dual combination of Isoniazid 
and Rifampicin for four months9
Treatment Categories and Drug Regimens
Standardized Treatment Regimens are one of the pillars of the DOTS strategy14
Isoniazid,  Rifampicin,  Pyrazinamide,  Ethambutol, and  Streptomycin are the primary 
antitubercular  drugs  used.  Most  DOTS  regimens  have  thrice-weekly  schedules  and 
typically last for 6 to 8 months, with an initial Intensive phase and a Continuation phase.
Based on the Nature/severity of the disease and the Patients' exposure to previous 
anti-tubercular  treatments,  RNTCP classifies  tuberculosis  patients  in  to  three  treatment 
Categories.
Category I Category II Category III
• New sputum smear-
positive
• Seriously ill sputum 
smear-negative
• Seriously ill 
extra-pulmonary
• New Sputum 
Positive/Negative HIV 
Positive
• Sputum smear-positive 
Relapse
• Sputum smear-positive 
Failure
• Sputum smear-positive 
Treatment after default
• Sputum smear negative 
Others/Chronic
• New  sputum  smear-
negative,  not 
seriously ill 
• New  extra-pulmonary, 
not seriously ill
   2H3R3Z3E3 + 4H3R3
2H3R3Z3E3S3 +  1H3R3Z3E3 + 
5H3R3E3
        2H3R3Z3 + 4H3R3
2 months Intensive phase + 4 
months continuation phase 
Four  drugs  at  Thrice-weekly 
Schedule
3 months  Intensive  phase  + 5 
months continuation phase 
Five  drugs  at  Thrice-weekly 
Schedule
2 months Intensive phase + 4 
months continuation phase 
Two drugs at Thrice-weekly 
Schedule
H:  IsoniaziD (600 mg),  R:  Rifampicin (450 mg),  Z:  Pyrazinamide (1500 mg),  E: 
Ethambutol (1200 mg), S: Streptomycin (750 mg)
Second line Drugs15
Bactericidal Bacteriostatic
Amikacin (Am)
Capreomycin (Cm)
Ciprofloxacin (Cx)
Ethionamide (Et)
Kanamycin (Km)
Ofloxacin (O)
Protionamide
Cycloserine (Cs)
p-aminosalycilic acid (PAS)
Isoniazid16 (isonicotinic acid hydrazide; C8H7N3O, MW: 137.1)
 
Isoniazid is one of the most powerful drugs against TB. INH is a pro-drug that 
requires processing by the bacterial catalase-peroxidase to become active. Once activated, 
it  inhibits  the  biosynthesis  of  mycolic  acids,  which  are  essential  components  of  the 
mycobacterial cell wall. This drug is bactericidal against metabolically active bacilli and 
bacteriostatic against resting bacilli. INH is active against M. tuberculosis, M. bovis and M. 
kansasii. Susceptible M. tuberculosis strains show minimal inhibitory concentrations (MIC) 
between 0.02 and 0.2 mg/ml. Mutations leading to INH resistance have been identified in 
different gene targets including KatG, inha, ahpc and other genes remain to be established17
Rifampicin16
RIF,  a  lipophilic  ansamycin,  is  5,6,9,17,21-Hexahydroxy-23-mothoxy-
2,4,12,16,18,30,22-heptamethyl-8-(N-(4-methyl-1-piperazinylformimidoyl)-
2,7(epoxypentadecal(1,11,13) trienimino) naptha (2,1-b) furan-1,11 (2H)-dione-21 acetate, 
chemically. It is a highly active mycobactericidal drug because it diffuses rapidly across the 
hydrophobic cell envelope.
RIF  inhibits  gene  transcription,  by  interacting  with  the  beta  subunit  of  the 
ribonucleic  acid  (RNA)  polymerase  enzyme.  It  is  bactericidal  against  dividing 
mycobacteria  and  also  has  some  activity  against  non-dividing  bacilli.  M.  tuberculosis  
strains  are  normally  susceptible  to  0.1-2 mg/L.  The introduction  of  RIF,  thus,  allowed 
reduction of the duration of standard antituberculosis  treatments  from one year  to nine 
months.
The conformational relationship between the aliphatic chain and the aromatic nucleus is 
very important for microbiological activity, probably because of the interaction of the drug 
with its target. 
Rifampin (RIF) resistance serves as a surrogate marker for the detection of MDR 
TB, as 90% of Rifr isolates are also isoniazid resistant. RIF interferes with transcription and 
elongation of RNA by binding to the DNA-dependent RNA polymerase. It was observed 
that resistance to RIF follows a single-step, high-level resistance pattern in which mutations 
occur  spontaneously  at  a  frequency  of  1029.  The  genetic  basis  for  RIF  resistance  in 
approximately 95% of the cases is due to mutations in an 81-bp RIF resistance-determining 
region (RRDR) of the  rpoB  gene, corresponding to codons 507 to 533 (Escherichia coli 
numbering  system),  which  codes  for  the  beta  subunit  of  the  RNA  polymerase  of  M. 
tuberculosis18.
DRUG RESISTANCE
Historical aspects of Drug Resistance in M.tuberculosis.
Drug resistance as a limiting factor for success of chemotherapy of tuberculosis was 
recognized almost immediately following monotherapy of Streptomycin, the first effective 
antituberculous  drug19.  Though there a  striking improvement  in  the patient’s  symptoms 
initially, the condition of the patient soon deteriorated with increase in number of bacilli in 
the sputum. The bacilli isolated at that time instead of being killed by the drug, continued 
to grow in-vitro, in the presence of high concentrations of the drug. 
The classical  observation  was  followed  by another  important  finding  by20,  who 
showed that  during treatment  with Streptomycin  alone,  the proportion of drug resistant 
bacilli increased progressively from about one in 88,750 organisms before the therapy to 
about one in 367 after  15 weeks of treatment.  These observations  were the pioneering 
studies on drug resistance in M.tuberculosis.
Subsequent studies by two pioneering scientists21 showed that with monotherapy or 
inadequate therapy, the number of susceptible bacilli decreased while the resistant bacilli 
increased in lung cavities of the patients. This was called the fall and rise phenomenon.
The international group of specialists assembled by the WHO in 1969 adopted the 
definition of drug resistance of M.tuberculosis after testing a large number of wild strains 
against three drugs available during that period22
DEFINITION
Drug resistant tuberculosis is defined as a case of tuberculosis excreting bacilli resistant to 
one or more anti-tubercular drugs. 
Multi-drug  resistant  tuberculosis  (MDR-TB)5 is  defined  as  disease  due  to 
M.tuberculosis that  is  resistant  to  Isoniazid  (H)  and  Rifampicin  (R)  with  or  without 
resistance to other drugs
Extensively drug resistant tuberculosis (XDR-TB)23 is resistance to at least Isoniazid and 
Rifampicin  (i.e.  multidrug-resistant  TB  or  MDR-TB),  plus  resistance  to  any 
fluroquinolones,  and  any  one  of  the  second-line  anti-TB  injectable  drugs  (Amikacin, 
Kanamycin or Capreomycin). 
TYPES OF DRUG RESISTANCE
On epidemiological grounds, drug resistance has been divided into 3 broad categories 
discussed below. The definitions are used in mass surveys to assess the prevalence of drug 
resistance in the community or the country. Such surveys conducted at frequent intervals 
could  be  used  to  monitor  the  success  of  treatment  programs,  particularly  if  a  national 
treatment  policy  is  implemented  and  thus  serve  as  epidemiological  yard  sticks24. The 
categories are as follows:
1. Primary  Drug  Resistance,  where  the  drug-resistant  bacilli  are  isolated  from 
previously untreated patients.
2. Acquired  drug resistance,  where  resistant  bacilli  are  isolated  from patients  who 
originally homed in the susceptible bacilli
3. Initial Drug Resistance denotes drug resistance in patients, who deny a history of 
previous chemotherapy. In actual terms it consists of true primary resistance with a 
mixture of an unknown amount of undisclosed acquired drug resistance. Because it 
takes elaborate efforts on the part of the health authorities to obtain information on 
the possibility of previous treatment, which is unreported, initial drug resistance has 
been gaining practical importance.
Factors responsible for the development of drug resistance:25
The emergence of drug resistance in M.tuberculosis has been associated with a variety 
of management, health provider and patient-related factors.
(i) Deficient or deteriorating TB control programmes resulting in inadequate 
administration of effective treatment; 
(ii) Poor case holding, administration of sub-standard drugs, inadequate or irregular 
drug supply and lack of supervision;
(iii) Ignorance of health care workers in epidemiology, treatment and control; 
(iv) Improper prescription of regimens; 
(v) Interruption of chemotherapy due to side effects;
(vi) Non-adherence of patients to the prescribed drug therapy;
(vii) Availability of anti-TB drugs across the counter, without prescription; 
(viii) Massive bacillary load; 
(ix) Illiteracy and low socio-economic status of the  patients; 
(x) The epidemic of HIV infection; 
(xi) Laboratory delays in identification and susceptibility testing of M. tuberculosis 
isolates; 
(xii) Use of nonstandardized laboratory techniques, poor quality drug powders and 
lack of quality control measures; and
(xiii) Use of anti-TB drugs for indications other than tuberculosis.
Various Gene Loci conferring drug resistance to MTB  26  
Drug Gene Gene product/functional role Cellular target
Rifampicin rpoB B-subunit  of  RNA 
polymerase/transcription
Nucleic acids
Isoniazid katG 
oxyR-ahpC
kasA
Catalase-peroxidase/activation  of 
Pro-drug 
Alkyl-hydro-reductase/unknown
b-ketoacyl acyl carrier protein
Cell wall
INH-
Ethionamide 
inhA Enoyl-ACP reductase/synthase
Mycolic acid synthesis 
Cell wall
Streptomycin rpsL 
rrs
Ribosomal protein S12 /translation 
16S rRNA/translation
Protein synthesis
Fluoroquinolon
e 
gyrA DNA gyrasde Nucleic acid
Pyrazinamide pncA Amidase/activation of pro-drug Unknown
Ethambutol embB Arabinosyl  transferase/arabinan 
polymerization
Cell wall
LAB DIAGNOSIS
The key to the diagnosis of tuberculosis is a high index of suspicion. Often, the 
diagnosis is first entertained when the chest radiograph of a patient being evaluated for 
respiratory symptoms is abnormal. The longer the delay between the onset of symptoms 
and  the  diagnosis,  the  more  likely  is  the  finding  of  cavitary  disease.  In  contrast, 
immunosuppressed  patients,  including  those  with  HIV  infection,  may  have  “atypical” 
findings on chest radiography e.g., lower-zone infiltrates without cavity formation. 
PPD Skin Testing
Skin  testing  with  PPD  is  most  widely  used  in  screening  for  M.  tuberculosis 
infection. The test is of limited value in the diagnosis of active tuberculosis because of its  
low sensitivity and specificity. False-negative reactions are common in immunosuppressed 
patients and in those with overwhelming tuberculosis. Positive reactions are obtained when 
patients have been infected with M. tuberculosis but do not have active disease and when 
persons have been sensitized by nontuberculous mycobacteria or bacille Calmette- Gue´rin 
(BCG) vaccination27
A presumptive diagnosis is commonly based on the finding of AFB on microscopic 
examination of a diagnostic specimen such as a smear of expectorated sputum or of tissue 
Diagnosis of Latent Tuberculosis Infection 
QuantiFERON®-TB  gold (The  Whole  Blood  IFN-gamma  Test  Measuring 
Responses to ESAT-6 & CFP-10 Peptide Antigens) 
QuantiFERON®-TB Gold is an indirect test for M. tuberculosis infection (including 
disease) and is intended for use in conjunction with risk assessment, radiography and other 
medical and diagnostic evaluations.
The QuantiFERON®-TB Gold is a test for Cell Mediated Immune (CMI) responses 
to  peptide antigen  cocktail  simulating  the mycobacterial  proteins  ESAT-6 and CFP-10. 
These  proteins  are  absent  from  all  BCG  strains  and  from  most  non-tuberculosis 
mycobacteria with the exception of  M. kansasii, M. szulgai  and M. marinum. Individuals 
infected with M. tuberculosis complex organisms usually have lymphocytes that recognise 
these  mycobacterial  antigens.  This  recognition  process  involves  the  generation  and 
secretion of the cytokine, IFN-γ. The detection and subsequent quantification of IFN forms 
the basis of this test.
The QuantiFERON®-TB Gold test is both a test for LTBI and a helpful aid for 
diagnosing  M. tuberculosis complex infection in sick patients. A positive result supports 
the diagnosis of tuberculosis disease; however, infections by other mycobacteria (e.g.,  M. 
kansasii) could also lead to false positive results28.
SAMPLE COLLECTION29
The number of specimen required for diagnosis of smear positive pulmonary TB is 
two, with one of them being a morning sputum specimen.
Two sputum specimens are collected over one, or two consecutive days. Of the two 
sputum specimens, one is collected on the spot and the other is an early morning specimen 
collected at home by the patient. One specimen positive out of the two is enough to declare 
a patient  as smear  positive TB.  Smear  positive TB is  further  classified as a new or re 
treatment  case  based  on  their previous  treatment  history,  and  appropriate  therapy  is 
prescribed.
Other  respiratory  specimens  include  induced  sputum,  tracheal  aspirate, 
bronchoalveolar lavage, pleural fluid and lung biopsy tissue.
AFB microscopy
 Most modern laboratories processing large numbers of diagnostic specimens use 
auramine-rhodamine staining and fluorescence microscopy. The more traditional method 
-light microscopy of specimens stained with Kinyoun or Ziehl-Neelsen basic fuchsin dyes-
is satisfactory, although more time-consuming.
Grading of AFB smears by Z-N microscopy30
No of acid-fast bacilli 
(AFB)
Fields Report
No AFB In 100 immersion fields Negative
1-9 AFB In 100 immersion fields* Record exact figure
(1-9 AFB/ 100 fields)
10 to 99 AFB In 100 immersion fields 1+
1 to 10 AFB Per field (examine 50 fields) 2+
More than 10 AFB Per field (examine 20 fields) 3+
DETECTION OF MTB
Processing of sample - concentration methods
`The most commonly used decontamination and concentration method for sputum 
samples are Modified Petroff’s method and NALC (N Acetyl L cysteine) method.
Conventional culture method
For detection  of Mycobacteria  in clinical  specimens the current “gold standard” 
consists of a combination of solid and liquid media9. In detecting as few as 101 – 10 2 viable 
organisms per ml of specimen in the optimal case, culture is more sensitive than smear. 
Also it is the only reliable means to monitor effectiveness of therapy in TB patients31
Specimens may be inoculated onto egg- or agar-based medium (e.g., Lowenstein-
Jensen or Middlebrook 7H10) and incubated at 37ºC under 5% CO2. Because most species 
of mycobacteria, including  M. tuberculosis, grow slowly, 4 to 8 weeks may be required 
before growth is detected. Although  M. tuberculosis may be presumptively identified on 
the  basis  of  growth  time  and  colony  pigmentation  and  morphology,  a  variety  of 
biochemical tests have traditionally been used to speciate mycobacterial isolates. In today’s 
laboratories, the use of liquid media for isolation and speciation by nucleic acid probes or 
high-pressure liquid chromatography of mycolic acids (HPLC) has replaced the traditional 
methods of isolation on solid media and identification by biochemical tests. These new 
methods have decreased the time required for bacteriologic confirmation to 2 to 3 weeks13
Rapid  and  sensitive  detection  of  Mycobacterium  tuberculosis is  of  clinical 
importance for the treatment, control, and prevention of tuberculosis. Despite new nucleic 
acid  amplification assays,  unequivocal  diagnosis  of  tuberculosis  continues  to  rely on 
cultivation of M. tuberculosis.
Automated culture method32
The fully automated systems that allows continuous monitoring of mycobacterial cultures 
are
1) BACTEC 460
2) MB/BacT 
3) ESP culture system II 
The BACTEC 460 system (Becton Dickinson, Sparks, Md.) has been marketed since 
1977. The Middle brook 12B medium for this system contains 14C labeled palmitic acid as 
the substrate. During mycobacterial growth,  14C -labeled  14CO2 is produced and released 
into the headspace air of the vials. A 14CO2 detection device allows early determination of 
mycobacterial growth. However, this system requires radioactive reagents, causing waste 
problems,  and vials  have to be handled and punctured for readings at  least  eight  times 
during 6 weeks of incubation, requiring a considerable amount of work and increasing the 
risk of cross contamination. 
The  recently  developed  MB/BacT  system (Organon  Teknika,  Turnhout,  Belgium) 
relies on a continuous colorimetric CO2detection device to indicate mycobacterial growth 
in a closed system. A solid-state sensor at the base of each vial contains the colorimetric  
indicator,  which changes from green to yellow when CO2  is produced in the vial.  Each 
compartment of the instrument where the vials are incubated contains a reflectometer and a 
detection unit.
ESP culture system II is based on the detection of pressure changes in the head space 
above the broth medium resulting from gas production or consumption due to growth of 
micro organisms
Other phenotypic detection methods
The fast plaque TB (Biotech Labs Ltd., Ipswich, UK) is a rapid manual test for the 
detection  of  M.  tuberculosis from  clinical  specimens  within  48  h33. This  test  utilizes 
specific  mycobacteriophages  (Actiphage™)  to  reflect  the  presence  of  viable  M. 
tuberculosis. Mycobacteriophages are added to a clinical specimen and allowed to incubate 
for one hour to allow phage infection of target tubercle bacilli. After the incubation period, 
a virucidal solution (Virusol™) is added, which destroys all phages that have not infected 
the bacilli. The remaining phages replicate in the infected bacilli until new progeny phages 
are released as the cells lyse. The progeny phages are amplified by the addition of a non-
pathogenic rapidly growing mycobacterial host M. smegmatis (Sensor™ cell), which is also 
able to support phage replication. This is visualized as plaques, which are clear areas in a 
lawn of Sensor™ cell growth. The number of plaques visualized is directly related to the 
number of viable tubercle bacilli in the original sample.
Mycolic acid analysis (HPLC)
Mycolic acids are present in all mycobacteria. Their composition is constant for all 
strains of a given species and varies from species to species. An HPLC method for analysis 
of mycolic acid esters, has been standardized and demonstrated to be a rapid and reliable 
method for identification of many mycobacterium species34
In  this  procedure,  mycolic  acids  are  extracted  from  saponified  mycobacteria, 
converted to p-bromophenacyl esters, and analysed by HPLC. The mycolic acid esters are 
separated  on  a  reversed-phase  C18 column by a  methanol-methylene  chloride  gradient 
elution and detected by UV or fluorescence detection spectrophotometry.
The  standardized  method  recommends  a  visual  comparison  of  a  sample  HPLC 
pattern on an atlas of reference strain patterns in combination with the use of peak height 
ratios.
GENOTYPING METHODS FOR DETECTION OF M.TUBERCULOSIS 35
DNA probes: 
Based on information about specific gene sequences well defined oligonucleotide 
probes for identification of various clinically relevant mycobacteria have been developed 
and  are  readily  available.  These  probes  are  being  used  in  several  countries  for  rapid 
confirmation  of  the  identity  of  mycobacterial  isolates.  When  used  along  with  newer 
methods of detection of the early growth (such as BACTEC, Septi-Chek, MGIT) these are 
of great help in rapidly confirming the diagnosis as identity of isolate can be established 
within  1  to  2  days  with  gene  probes  as  compared  to  much  longer  time  required  with 
classical biochemical tests
INNO LIPA 
The LiPA assay is  based on the  principle  of reverse hybridization.  Biotinylated 
DNA material, obtained by means of a PCR amplification of the 16S-23S ribosomal RNA 
spacer region, is hybridized with 14 specific oligonucleotide probes immobilized as parallel 
lines on membrane strips. The addition of streptavidin labeled with alkaline phosphatase 
and of a chromogenic substrate results in a purple-brown precipitate on hybridized lines.
Gene  amplification  methods  for  direct  detection  of  M.tuberculosis sequences  from 
clinical specimens:
 Gene  amplification  techniques have  made  a  major  impact  on  the  diagnosis  of 
mycobacterial  diseases. These methods may be classified as those based on polymerase 
chain  reaction (PCR)  and  others  based  on  isothermal  amplification reactions.  Gene 
amplification techniques are highly sensitive and under optimum conditions may detect 1-
10  organisms.  If  systems  are  adequately  standardized,  evaluated  and  precautions  for 
avoiding the contamination are taken,  these assays  can play a very useful role in early 
confirmation of diagnosis in paucibacillary extra-pulmonary forms of tuberculosis.
PCR methods 
A variety of PCR methods have been developed for detection of specific sequences 
of M.tuberculosis targeting either DNA or rRNA/and these could be based on conventional 
DNA  based  PCR,  nested  PCR  and  RT-PCR.  Targets  include  insertion  and  repetitive 
elements, various protein encoding genes, ribosomal rRNA  etc. A large number of PCR 
assays targeting different gene stretches of M. tuberculosis have been described.  Different 
Indian investigators have used separate gene targets like MPB 6433, repetitive sequences , 
GC repeats  ,  devR ,  38kD ,  TRC  4 ,  IS 1081 and a  system patented  by Central  Drug 
Research Institute (CDRI), Lucknow. Some of these assays (CDRI) have been repeatedly 
found to be reproducible, highly sensitive and specific in double blind evaluations. IS-1081 
based system has been further modified and a new nested PCR target of this gene has been 
developed at Centre for DNA Fingerprinting and Diagnostics (CDFD), Hyderabad. This 
strategy can be used for confirming the diagnosis and also monitoring the progress.
Isothermal amplification techniques: 
These  techniques  represent  a  major  step  forward  in  the  application  of  gene 
amplification technology without thermal cycler. The important methods are:
(i) Strand displacement amplification (SDA): 
It is an isothermal in vitro nucleic acid amplification technique which is based upon 
the ability of HincII  to  nick the unmodified strand of hemiphosphorothiote  form of its 
recognition site and the ability of exonuclease deficient klenow to extend 3’ end at the nick 
and displace the downstream DNA strand. Exponential amplification results from coupling 
sense and antisense reactions.
(ii) Gene probe amplified Mycobacterium tuberculosis direct test:
 This assay employs the isothermal amplification of M. tuberculosis complex rRNA 
followed by detection  of  amplicon with  acridinium ester-labelled  DNA probe. Reports 
about the application of this system are encouraging.
(iii) Q-beta (QB) replicase based gene amplification: 
This approach involves production of RNA in the amplification reaction using QB 
replicase as the enzyme and reaction at  fixed temperature (for example 37°C). Using a 
suitable combination of capture and detector probes, sensitivity up to one colony forming 
unit has been reported for M. tuberculosis. Further, the inhibitors of PCR were observed to 
have no effect on this assay.
Gene amplification methods for identification and speciation of M.tuberculosis
Different  strategies  to  identify  the  isolates  from cultures  and  directly  from the 
clinical  specimens  have  been  described.  These  include  amplification  of  specific  gene 
regions  followed  by  hybridization  with  species  specific  probes,  sequencing  and  RFLP 
analysis such as hsp 65 kDa gene 21, katG22 and rRNA genes (23-25, a CJIL system under 
publication) have been described. These PCR-RFLP assays help in quick identification of 
pathogenic  mycobacteria  including  M. tuberculosis from the culture isolates  as well  as 
directly from the clinical specimens. While PCR-sequencing approach can be applied by 
reference  laboratories  the  hybridization  and RFLP approaches  are  easily  practicable  in 
clinical mycobacteriology laboratories.
DRUG SUSCEPTIBILITY TESTING METHODS
Phenotypic methods26
Absolute concentration method:
This method uses a standardized inoculum grown on drug free media and the media 
containing graded concentrations of the drug to be tested. Several concentrations of each 
drug are tested, and the resistance is expressed in terms of the lowest concentration of the 
drug that inhibits the growth; i.e., minimum inhibitory concentration (MIC). This method is 
greatly affected by the viability of organisms.
Resistance Ratio method:
It compares the growth of unknown strains of M.tuberculosis with that of standard 
laboratory strain (H37Rv). Parallel sets of media containing two-fold dilutions of the drug 
are inoculated with the standard strains of tubercle bacilli. Resistance is expressed as the 
ratio of the MIC of the test strain to the MIC of the standard strain in the same set. This test 
is  also greatly  affected  by the inoculum size  as  well  as  the  viability  of  the strains.  In 
addition any variation in the susceptibility of the standard strain also affects the RR of the 
test strain.
Proportion method:
This method enables a precise estimation of the proportion of mutants resistant to a 
given drug. Several 10-fold dilutions of the inoculum are planted on to both control (drug 
free) and the drug containing media. At least one dilution should yield isolated countable 
(50-100) colonies.  When these numbers are adjusted by multiplying  the dilution of the 
inoculum used, the total number of viable colonies on the control medium and the number 
of  mutant  colonies  resistant  to  the  drug  concentrations  tested  may  be  estimated.  The 
proportion  of  the  bacilli  resistant  to  a  given  drug is  then  estimated  by expressing  the 
resistant portion as a percentage of the population used.
Microscopic Observation Drug Susceptibility Assay (MODS)36: 
The microscopic-observation drug-susceptibility (MODS) assay is a low-cost, low-
tech tool for high-performance detection of TB and MDRTB. The MODS assay is based on 
three  principles:  1)  M.tuberculosis grows  faster  in  liquid  media  2)  microscopic 
M.tuberculosis growth is characteristic and can be detected earlier in liquid 3) the drugs 
Isoniazid  and  Rifampicin  can  be  incorporated  into  the  MODS  assay  to  allow  for 
simultaneous direct detection of MDRTB, obviating the need for subculture to perform an 
indirect drug susceptibility test.
Pha B assay:
This is a new phenotype culture drug susceptibility testing method named as phage 
amplified  biologically  (Pha B),  and is  based on the  ability  of  viable  M.tuberculosis to 
support the replication of an infecting mycobacteriophage:noninfecting exogenous phages 
are inactivated  by chemical  treatment.  The number  of endogenous phages,  which is  an 
indication of the original number of viable  M.tuberculosis, is determined after cycles of 
infection,  replication  and release  in  rapidly growing mycobacteria.  In  the  case of  drug 
resistant M.tuberculosis, bacilli will remain viable and protect the mycobacteriophage. Any 
mycobacteriophage protected within viable bacilli replicate and ultimately lyse their host. 
For  rapid  detection,  the  released  mycobacteriophages  are  mixed  with  rapidly  growing 
M.smegmatis host in which they undergo rapid cycle of infection,  replication and lysis. 
Lysis is easily seen as clear areas or plaques in a lawn culture of M.smegmatis. The number 
of  plaques  generated  from  a  given  sample  is  directly  proportional  to  the  number  of 
protected mycobacteriophages, which is dependent on the number of tubercle bacilli that 
remain viable after drug treatment.
Luciferase reporter phage assay:
In this technique, viable mycobacteria are infected with reporter phages expressing 
firefly luciferase gene. Easily detectable signals are seen a few minutes after the infection 
of  M.tuberculosis with  reporter  phages.  Light  production  requires  metabolically  active 
M.tuberculosis cells, in which reporter phages replicate and luciferase gene is expressed. 
When drug susceptible M.tuberculosis strains are incubated with specific anti-tuberculosis 
drugs, they fail to produce light after infection with luciferase reporter phages. In contrast, 
drug resistant strains are unaffected by the drugs and produce light at the levels equivalent 
to those documented for untreated controls after infection with reporter phages. The other 
reporter  molecules  described  is  the  green  fluorescence  protein  (GPF)  of  the  jellyfish 
Aequorea Victoria. This reporter system does not require cofactors or substances due to 
intrinsic fluorescence nature of the GPF. Luciferase reporter tests have now been evaluated 
against the four first-line antibiotics with an overall agreement of 98.6% compared with the 
BACTEC TB_460.
Colorimetric methods: 
Colorimetric methods are based on the reduction of a colored redox indicator added 
to the culture medium after MTB has been exposed invitro to different drugs. Resistance is 
detected by a change in colour of the indicator, which is directly proportional to the number 
of viable mycobacteria in the medium 
Different indicators have been evaluated for testing against first  and second-line 
drugs, giving comparable results in agreement with the gold standard proportion method. In 
a  multicentre  evaluation  to  assess  two  colorimetric  methods  using  the  MTT  (3-(4,5-
dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide) and  resazurin  as redox indicators 
for the first line drugs, very good results were obtained with sensitivity and specificity of 
99 and 96% respectively37.
The Nitrate Reductase assay 
The nitrate reductase assay (NRA) is a very simple technique based on the capacity 
of  M.tuberculosis to  reduce  nitrite.  M.tuberculosis is  cultivated  in  the  presence  of  an 
antibiotic and its ability to reduce nitrate is measured after 10 days of incubation. Resistant 
strains  will  reduce  the  nitrate,  revealed  by  a  pink-red  colour  in  the  medium,  while 
susceptible strains will lose this capacity as they are inhibited by the antibiotic38.
The test was recently evaluated for first and second line drugs with good results. 
The test  performed  very well  for  Isoniazid,  Rifampicin  and Ethambutol  with  accuracy 
between 96.6% and 98%. The main advantage of the NRA, in addition to its simplicity, is 
that  it  uses  the  same format  and culture  medium as  used  in  the  conventional  method, 
facilitating its implementation in diagnostic laboratories.
The  MGIT  system,  in  its  manual  or  automated  version  and  based  on  the 
measurement  of  oxygen  consumption,  has  been  thoroughly  evaluated  for  DST  of 
M.tuberculosis to first and second line drugs showing a good concordance with the gold 
standard PST method39
Radiometric  method to  detect  early  growth  of  mycobacteria  in  culture  is  the 
BACTEC 460 system, wherein C14  labelled palmitic acid in 7H12 medium is used. The 
system detects the presence of mycobacteria based on metabolism of C14 rather than visible 
growth. This method provides rapid growth, specific identification and drug susceptibility 
testing within 14 days26. The most common reported problems associated with BACTEC 
460  include:  the  risk  of  needle  puncture,  the  need  to  dispose  radioactive  waste,  and 
potential contamination of test samples 
 
Molecular Assays for detection of drug resistance. 
DNA sequencing: 
DNA  sequencing  of  PCR-amplified  products  has  been  the  most  widely  used 
method, becoming the gold standard. It has been performed by both manual and automated 
procedures although the latter has been the most commonly used. It has been thoroughly 
used for characterising mutations in the rpoB gene in Rifampicin resistant strains and to 
detect mutations causing resistance other anti-TB drugs. Several other genotypic methods, 
like  PCR-single  strand  conformation  polymorphism,  PCR-heteroduplex  formation  and 
solid phase hybridisation assays have been developed. 
Moreover, the line probe assay(LiPA-RIF) based on the hybridisation of amplified 
DNA from cultured strains or clinical samples to ten probes encompassing the core region 
of the rpoB gene of M.tuberculosis, immobilised on a nitrocellulose strip and the Genotype 
mycobacterium tuberculosis test (MTB) DR (Hain, Germany), a commercial system for the 
detection of the MTBC and its  resistance to Rifampicin and INH from culture samples 
based on the detection of the most common mutations in the rpoB gene and katG genes, 
respectively.
Genotype MTBDR Strip based test: 
The genotype MTBDR (Hain Life Science, Nehren, Germany) is a new commercial 
and easy to perform assay developed for the detection of RIF and/or INH resistance in TB 
strains.  The  test  is  based  on  reverse  hybridisation  between  amplicons  derived  from a 
multiplex PCR and nitrocellulose bound wild-type and mutated probes for the mutations of 
interest.  The  test  allows  rapid  and  specific  detection  of  most  mutations  conferring 
resistance not only to RIF but also to INH in M. tuberculosis isolates. This test combines 
the  probes  targeting  the  81-bp  “hot-spot”  region  in  the  rpoB  gene,  with  two  probes 
targeting two different mutations at position 315 of the katG gene. Mutations affecting this 
codon  are  responsible  for  INH  resistance  in  ca.60%  of  the  cases  worldwide.  The 
simultaneous detection of resistance to both RIF and INH allows an early diagnosis of an 
MDR case40
More recently DNA microarrays or high-density oligonucleotide arrays have been 
applied for species identification of mycobacteria. The method is based on hybridisation of 
fluorescently-labelled  PCR amplified  products  obtained from mycobacterial  colonies  to 
DNA arrays containing nucleotide probes
Real-time Polymerase Chain Reaction Techniques: 
Real time PCR techniques have also been introduced for rapid detection of drug 
resistance. Different probes have been used like the TaqMan probe, fluorescence resonance 
energy transfer (FRET) probes, molecular beacons and bio probes. The main advantages of 
real time PCR techniques are the speed of the test and a lower risk of contamination. The 
main disadvantages would be requirement for expensive equipment and reagents, and the 
need for skilled technical personnel. In several studies, real time PCR has been evaluated in 
culture material and more recently in clinical samples. The sensitivity in these studies has 
ranged from 71-98% with specificity close to 100 %41. The main advantage of the RT-PCR 
is its speed in giving results, 1.5-2 h after DNA extraction, and the decrease in the risk of 
contamination since both reaction and detection occurs in a single tube. Further studies are 
necessary to confirm the real value of this new methodology in the clinical setting.
Miscellaneous genotyping method:
These include new genotypic techniques for the rapid detection of drug resistance in 
M.tuberculosis. Cleavage fragment length polymorphism (CFLP), dideoxy finger printing 
(ddF), hybridization protection assays,  a technique based on reverse transcriptase strand 
displacement amplification of m-RNA, RNA-RNA duplex base-pair mismatch assay and 
DNA sequence analysis  using flurogenic reporter molecules.  However, these techniques 
have not been extensively studied and have not been further validated with clinical isolates. 
Although they share a high specificity common to all sequencing techniques, most of them 
rely on technically demanding procedures and in some cases need specialized and costly 
equipment precluding their use in laboratories.
                Materials & Methods  
MATERIALS AND METHODS42
A total of 117 respiratory specimens from patients attending the RNTCP outpatient 
clinic and from inpatients at PSG Hospitals during the period between June 2008 and June 
2009 were included in the study. Human ethical clearance for the study was obtained from 
the Institutional ethical committee prior to collection of samples. A copy of the certificate 
is attached.  The respiratory samples included were sputum, bronchoalveoaler lavage and 
pleural fluid. 
Sample collection  
About  5 to  10 ml  of  well  coughed up early morning and spot  sputum samples 
without  salivary  contamination  was  collected  in  a  sterile  wide  mouthed,  screw-capped 
container. BAL and Pleural fluid were received in a sterile container.  In case of a delay in 
processing immediately the samples were stored at 4ºC for not more than 24 hours.
All specimens that were positive for acid fast bacilli by Ziehl Neelsen staining of 
smears were included in the study.  Processing of all  samples  was done in a bio safety 
cabinet class IIB with Universal precautions.
Ziehl-neelsen staining procedure                  
A smear was made on a clean slide from thick purulent part of the sample.  The 
smears were dried, heat fixed and stained by the Ziehl-Neelsen technique.
1. Slides were placed on a staining rack with the smeared side facing up, ensuring  that 
the slides were not touching each other
2. Slides were flooded with strong carbol-fuchsin, which was filtered before use
3. Slides were heated intermittently until steaming for 5-7 minutes. Care was taken to 
see that the stain did not boil or dry out.
4. Each slide was rinsed individually in a gentle stream of distilled water until all free 
stain is washed away
5. Slides were flooded with the decolorizing solution (25 % sulphuric acid) for 2-3 
minutes.
6. Slides were rinsed again thoroughly with water. Excess water was drained off.
7. Slide was flooded with methylene blue counter stain for 30 seconds.
8. The slides were air dried after rinsing thoroughly and draining off excess water.
9. Under the oil immersion objective, acid fast bacilli were seen as slender pink rods 
while the non acid fast bacilli and the background appeared blue in colour.
Smear examination
Samples were examined by direct microscopy after staining by Ziehl Neelsen Stain and 
examined under oil immersion. Sputum smears were graded depending on the number of 
bacilli seen
Table 1: Grading of AFB smears by Z-N microscopy
No of acid-fast bacilli 
(AFB)
Fields Report
No AFB In 100 immersion fields Negative
1-9 AFB In 100 immersion fields* Record exact figure
(1-9 AFB/ 100 fields)
10 to 99 AFB In 100 immersion fields 1+
1 to 10 AFB Per field (examine 50 fields) 2+
More than 10 AFB Per field (examine 20 fields) 3+
Presence of acid fast bacilli >1 was taken as positive for BAL and Pleural fluid.
All sputum and BAL samples were decontaminated by Modified petroff’s method 
and 1-2 loopful of the deposit was inoculated on two Lowenstein Jensen medium using 
4mm diameter nichrome loop. Pleural fluid specimens were centrifuged at 3000g for 15 
minutes and the sediment was used as inoculum. 
Sodium hydroxide (modified petroff’s) method:
 To x ml of sputum,  2x  ml of 4% NaOH was added and mixed well
 The tubes were kept for 15 minutes at 37ºC with occasional shaking
 The  tubes  were  centrifuged  at  3000 g  for  15  minutes  and the  supernatant  was 
poured off taking care not to discard the sediment.
 Approximately 20 ml sterile distilled water was added to resuspend the sediment 
and the tubes were centrifuged again at 3000 g for 10 minutes 
 Supernatant  was  decanted  and  deposit  was  inoculated  onto  two  slopes  of  L-J 
medium. 
Culture
 The bottles were kept in racks and incubated for 8 weeks at 35-37ºC under aerobic 
atmosphere.
 It was then examined daily for 1 week (for any rapid growers, or for contamination, 
indicated by bluing, digestion of media, etc). Hand lens was used.
 The colonies  of  Mycobacterium tuberculosis were dry,  rough, irregular  colonies 
with a wrinkled surface and buff colour.
REPORTING OF POSITIVE, NEGATIVE AND CONTAMINATION RESULTS
Reading Report
No growth
1-19 colonies
20-100 colonies
>100 discrete colonies
Confluent growth
Contaminated
Negative
Positive (number of colonies)
Positive (1+)
Positive (2+)
Positive (3+)
Contaminated
A total of 104 positive cultures resembling  M.tuberculosis were subjected to biochemical 
tests and susceptibility to p-nitro benzoic acid for its identification
Biochemical tests
The following biochemical tests were used in identification of Mycobacterium tuberculosis 
complex.
NIACIN PRODUCTION TEST
A culture must be at least three to four weeks old and must have sufficient growth of at  
least 100 colonies.
Procedure
1. All the slopes were arranged and 1 ml sterile distilled water was added to the tube 
and dug to extract niacin
2. The bottles were left in slanting position for 30 minutes
3. The bottles were kept upright for 10min to allow the fluid to drain to bottom
4. 0.5 ml of the culture extract was pipetted into a clean screw-capped tube placed on 
a rack inside the Bio Safety Cabinet.
5. 0.5  ml  of  4%  aniline  in  alcohol  and  10%  cyanogen  bromide  were  added 
sequentially
6. The contents were mixed well and checked for appearance of canary yellow colour.
Controls:
Positive control:        Extract from culture of M.tuberculosis H37Rv strain
Negative control:       Extract from uninoculated bottle of medium.
CATALASE TEST at 68oC/pH 7.0
Procedure
1. With a sterile pipette, 0.5 ml of 0.067 M buffer was added aseptically into 16 x 125 
mm screw-capped test tubes
2. A loopful of the test culture was suspended in the buffer solution, using a sterile 
loop
3. The tubes with the emulsified culture were placed in a previously heated water bath 
at 68oC for 20 minutes. 
4. The tubes were removed from water bath and cooled to room temperature
5. Catalase reagent (0.5ml) was added and the tubes were observed for the formation 
of bubble appearing on the surface of the liquid. Tubes were not shaken because 
Tween-80 may also form bubbles when shaken, resulting in false positives.
6. Negative tubes were held for 20 minutes before discarding
Control:
Positive control: strain M.terrae complex
Negative control: strain M.tuberculosis, H37Rv strain
NITRATE REDUCTION TEST
Procedure
One loopful  of  culture  was  emulsified  in  one  test  tube  containing  2  ml  of  the  sterile 
substrate (sodium nitrate)
The contents were mixed well and incubated upright in a water bath maintained at 37ºC for 
2 hours
After 2 hours, the tubes were brought to room temperature. And the reagents were added in 
the following order:
1 drop of 1:1 HCl
o 2 drops of 0.2% sulphanilamide solution
o 2 drops 0.1%  N- (1-naphthyl)-ethylene diamine di-HCl   
Development of a pink to red color indicated a positive reaction.
All negative reactions were confirmed by adding a pinch of zinc dust. 
Development of a pink color at this stage indicated that the initial negative reaction was 
true negative. If no color change occurred after adding the zinc dust, the reaction has 
proceeded beyond nitrite into other components. The entire test was repeated.
Controls
Positive control : strain M.tuberculosis, H37Rv strain
Negative control: reagent control without organisms 
SUSCEPTIBILITY TO P-NITROBENZOIC ACID (PNB)
Procedure
• Two slopes of LJ medium without drugs and one slope of LJ medium containing  p-
nitrobenzoic acid (PNB) at a concentration of 500µg/ml were inoculated with the neat 
bacterial suspension equivalent to 0.5 Mcfarlands standard and incubated at 370C. 
• Reading was taken after 28 days.
Results and interpretation
M.tuberculosis does not grow on PNB medium.  
All other mycobacteria are resistant.
Drug susceptibility test 
Drug  susceptibility  testing  to  Isoniazid and  Rifampicin was  done  by  absolute 
concentration method. Standardization of procedure was done with standard strain H37Rv, 
known sensitive and multidrug resistant strains (for drug concentration in media, inoculum 
size, and optimum incubation period required for sensitivity testing of both RIF and INH).
Once  standardized,  the  results  were  applied  to  101 consecutive  clinical  isolates 
sensitive  to  PNB after  being  identified  as  M. tuberculosis by  culture  and  biochemical 
methods.
 Test  media  used:  Lowenstein-Jensen medium with drug concentrations  as given 
below.
       Table 2:   Drug concentrations (µg/ml)
Drugs H37Rv Test strain
Isoniazid  
Rifampicin
0.025, 0.05, 0.1, 0.2, 1.0, 5
4, 8, 16, 32, 64, 128
0.2, 1, 5
32, 64, 128
 Anti mycobacterial drugs tested - Rifampicin (RIF) and Isoniazid (INH) obtained 
from Sigma laboratories. 
Absolute concentration (MIC) method
Bacterial suspension
• Sterile tubes labeled with lab number of the culture to be tested were taken.
• Using  sterile  pipette  0.2ml  of  sterile  distilled  water  was  added  to  each  tube,  each 
containing 6- 10 glass beads.
• Using a 2 mm internal diameter 24 SWG wire loop, a loopful of representative sample 
of the bacterial mass which is approximately equal to 4 mg moist weight was gently 
dispersed into the tube.
• The tube was vortexed for 30 to 60 seconds to produce a uniform suspension.
• Gently shake the tube after adding 0.8 ml of sterile distilled water. The suspension was 
left inside the cabinet for 15-20 minutes for the coarser particles to settle down.
• Using  a  4mm external  diameter  27  SWG nichrome  wire  loop,  one  loopful  of  this 
suspension  was  inoculated  on  each  slope  of  the  test  media  containing  graded 
concentrations of the drug.
• Two drug free slopes (control) and one drug containing slope of each concentration of 
the drug(s) was inoculated for each strain tested.
•..................................................................................................................................The 
standard strain H37Rv was tested with each batch of test.
• The lab number of the cultures was recorded in the DST register with date.
Incubation and reading of the tests
•..................................................................................................................................The 
inoculated slopes were incubated and looked for growth after 28 days of incubation. 
•..................................................................................................................................  In  this 
method ‘growth’ is defined as the presence of 20 colonies or more. 
•..................................................................................................................................As  each 
slope was examined,  the results were recorded as follows:
3+ Confluent growth 
2+ Innumerable colonies (>100 colonies)
1+ 20-100 colonies
1-19 Actual number of colonies
• If the drug-free control slope yielded 100 colonies or less, the test was repeated from 
the control slope. 
• The lowest concentration of the drug inhibiting growth (MIC) was recorded
• The MIC at which the isolates were considered resistant were 0.2µg/ml for Isoniazid 
and   32µg/ml for Rifampicin
MTT ASSAY43
A total  of  70  isolates  of  Mycobacterium tuberculosis  strains  obtained  from the 
sputum samples were tested by MTT method. The test was standardized with respect to 
the inoculum size and optimum incubation period required for sensitivity testing of both 
RIF and INH
Four known  Mycobacterium tuberculosis strains tested by absolute concentration 
method (Two sensitive i.e., sensitive control-SC and two resistant i.e., resistant control-
RC to both the drugs) and one standard sensitive (SS) H 37 Rv strain received from the 
stock cultures were used. 
 Test media used: Middle brook 7H9 broth supplemented with 10% OADC 
(Oleic acid, albumin, dextrose and catalase) and 0.01% glycerol (Hi Media).
 MTT  solution-  (3-4,5-dimethylthiazol-2-yl-2,5-diphenyl  tetrazolium 
bromide) obtained from Hi Media.
Standardization of Inoculum Size
An inoculum of about 8 ml was prepared by suspension of colonies from three to 
four  week-  old  LJ  slopes  in  7H9 medium for  SC (Sensitive  control),  RC (Resistant 
control)  and SS (Standard  sensitive-  H37RV strain).  Different  concentrations  ranging 
from 10 7 cfu/ml (McFarland no.1), to 10 5 cfu/ml were made by serial tenfold dilution. 
Each concentration was sub cultured on 5% sheep blood agar to rule out contamination 
by  other  organisms  before  putting  up  the  test.  Each  concentration  containing  8  ml 
suspension was then  distributed  in  seven sterile  screw cap tubes  in  1ml  amount  and 
incubated for 7 days at 37°C. 
Every day one of the tubes from each concentration was tested by MTT assay and 
tubes  were  inspected  for  appearance  of  purple  colour.  From  this  experiment,  a 
concentration of 10 7 cfu/ml  was  found to give the colour change at the earliest and 
hence was taken as the standard inoculum size for the further testing.
Standardization of the Incubation Time
To optimize the period of incubation for each drug, the test was put in four sets of 
four tubes (i.e. Resistant control , Sensitive control, Drug free control and Blank control) 
and the tubes were incubated at 37°C for 2, 3, 4, 6 days for RIF and 4, 6, 7, and 9 days 
for INH, prior to the MTT assay. For RIF testing, 0.5 ml of standardized inoculum was 
added to 0.5 ml of RIF solution containing a concentration of 2μg/ml so as to get a final 
concentration of 1μg/ml. To obtain 0.2μg/ml of final drug concentration for INH, 0.1 ml 
of inoculum was added to the tube containing 0.9 ml solution i.e., 0.4 ml plain 7H9 and 
0.5 ml drug medium.  For each of the resistant  and sensitive isolate  tested,  drug free 
controls containing 0.5 ml of standard inoculum and 0.5 ml of plain 7H9 were included. 
Blank controls  containing  only drug solution and media  were set  up for colorimetric 
reading. 
Procedure
The assay was performed by adding 10μl of MTT solution into each tube (i.e., drug 
containing tubes, drug free control tubes and blank control) on the respective days of 
reading and the tubes were incubated for four hours at  37°C. One ml of solubilising 
solution containing 0.1N Hydrochloric acid in isopropanolol was then added to the tubes 
and the contents were mixed thoroughly by inverting the tubes. After half to one hour of 
incubation at room temperature, any change in colour to purple in each tube was recorded 
visually. The strain showing colour change to purple in both control and drug containing 
tube was labeled as resistant while strain showing colour change in drug free controls and 
no change in drug containing tube was labeled as sensitive strain. 
GENOTYPIC METHODS
1. PCR
Cultures which showed resistance to both drugs and resistance to Rifampicin were 
subjected  to  DNA extraction,  amplified  using  specific  primers  targeting  the  rpoB gene 
81bp region and sequenced for identification of mutation
a. Extraction of DNA from Mycobacterium tuberculosis44
1. One to two loopful of the colonies from LJ slopes were suspended in 0.5 ml of 
sterile Milli Q water, in a 1.5 ml Eppendorf tube.
2. The tubes were kept at 85° C for 30 minutes in a waterbath.
3. The tubes were centrifuged at 10000 RPM for 10 minutes at 25° C and the 
supernatant was discarded. To the pellet, 100 µl of TE buffer was added.
4. The contents were treated with 50µl of lysozyme (20mg/ml) and incubated at 37° C 
for 1hour to degrade the cell wall.
5. 70µl of 10% SDS + 6µl of 10 mg/ml proteinase K were added to precipitate the 
proteins.
6. The tubes were vortexed until the pellet was redistributed and later incubated for 10 
minutes at 65° C.
7. 100µl of 5M NaCl + 80µl of CTAB-NaCl was added to precipitate polysaccharides 
and residues and incubated at 65° C for 10 minutes.
8. To the tubes, 800 µl of chloroform (CHCl3) + iso-amyl alcohol (24:1) was added 
[used  to  remove  proteins  from  preparations  of  nucleic  acids.  CHCl3  denatures 
proteins, while iso-amyl alcohol reduces foaming during extractions and facilitates 
separation into aqueous and organic phase].
9. The tubes were centrifuged at 10000 RPM for 10 minutes.
10. The supernatant was transferred to a fresh tube and 600µl of ice cold iso-propanolol 
was added (to precipitate the DNA).
11. The tubes were incubated at -20° C, overnight.
12. The next day the tubes were centrifuged at 12000 rpm for 10 minutes at 40C
13. The contents were discarded and the pellet was washed with 1 ml of 70% ice-cold 
absolute  alcohol  (if  too  much  of  protein  contamination  occurred,  this  step  was 
repeated twice).
14. The contents were discarded, by tapping on a clean filter paper and the tubes were 
kept open at 45° C until dry.
15. The resulting pellet was re-suspended in 40µl of TE buffer until required for usage.
b. Amplification by PCR
Primer used for amplification of 81bp region on the rpoB gene
Forward primer 5’ GGTGGAAACCGACGACATCGA 3’
Reverse primer 5’ CGCATCGATCGGCGAATTGG 3’
Table 3: Volume of reagents used
PCR master mix 1X For 9 samples – 10X
Taq Buffer 2µl 20µl
dNTP mix 0.8 µl 8 µl
Primer – forward
 (200mM)
1 µl 10 µl
Primer – backward
(200mM)
1 µl 10 µl
Taq DNA Polymerase 0.4 µl 4 µl
Water 12.8 µl 128 µl
Total 19 µl
19 µl of the master mix was aliquotted to each labeled PCR tube. 1 µl of DNA was added 
to the corresponding tubes and PCR amplification was run using Eppendorf thermocycler.
c. PCR cycle
Each cycle comprised of an initial denaturation at 94 º C for 5 minutes and 40 cycles of 
denaturation at 94 ºC for 45 sec, annealing at 65 ºC for 50sec and amplification at 72 ºC for 
45 sec with a final extension at 72 ºC for 5 minutes
Detection of PCR products by gel electrophoresis
At the end of the reactions, a 1.5% gel was prepared with agarose and the PCR products 
were run using the electrophoresis kit to look for amplified products.
1.5% Gel preparation
1. To 20 ml of 1X TBE buffer, 300mg of agarose was added and the contents were 
heated in a microwave until it formed a clear solution.
2. To this  1µl of ethidium bromide was added and the solution was poured into a 
trough with comb.
3. The solution was allowed to set for approximately 30 minutes.
4. Once set, the comb and the tape around the trough was removed.
5. The trough was placed in an electrophoresis tank containing 1X TBE buffer. The 
trough should just immerse in the buffer.
6. Loading dye was mixed with 500bp ladder and each extracted DNA separately in 
sterile PCR tubes
7. Ladder was added to well no 4 and the other wells were loaded with the amplified 
DNA in order on either side of the marker.
8. Electrodes were connected and run at 100v for 45 minutes until the loading dye was 
seen at 3/4th of the gel.
9. The trough was removed and gel was viewed under UV illuminator for the presence 
of bands.
2. DNA sequencing
a. Sample preparation
DNA from the culture was amplified to obtain a volume of 100µl. This was purified 
by following the steps in the PCR purification kit (GENEI). 
b. DNA Sequencing was done for the amplified products (Macrogen.Inc)
    _     ___Results
Out  of  the  117  respiratory  samples  collected  for  the  identification  and  drug 
susceptibility  testing  of  Mycobacterium  tuberculosis,  104  (88%)  were  sputum,  11(9%) 
were bronchoalveolar lavage, and 2 (2%) were pleural fluid as shown in Fig 1.
The RNTCP sputum grading ranged from scanty to 3+.  The distribution of various 
grades and the percentage of sputum samples for each grading are shown in Fig 2
Of the 117 specimens processed, 13 had no growth and 3 samples showed growth 
on Lowenstein Jensen medium with p-nitro benzoic acid (PNB). Out of the 104 positive 
cultures, 3 which were resistant to PNB were excluded. 
The proportion of the males was more than the females in the 101 cases from whom 
cultures were positive and included in the study. The percentage of males and females was 
76% and 24% respectively giving a ratio of 3:1 (Fig 3)
The age distribution shown in Fig4 indicates the preponderance of tuberculosis in 
the fourth and fifth decade of life with the next common occurrence being in the age groups 
35 – 44 and 55 - 64. Most of the specimens were from new cases (80%) and only 20% 
comprised of old cases which included relapse and default cases
On the basis of a panel of 3 tests the isolates were identified and characterised as 
belonging to M.tuberculosis complex. Isolates of Mycobacterium tuberculosis complex are 
positive for Niacin and Nitrate tests with negative Catalase test. Niacin test was positive in 
71% isolates,  Nitrate  reduction in  75% and Catalase was negative  in  100% of  isolates 
(Fig5).  
Drug  susceptibility  test  done  by  absolute  concentration  method  for  2  drugs  – 
Isoniazid and Rifampicin, shows that 94% of the isolates were sensitive to both the drugs. 
The presence of >20 colonies at the MIC of ≥ 0.2µg/ml for Isoniazid and at ≥ 32 µg/ml for 
Rifampicin was seen in 5 isolates and was categorised as Multi-drug resistant strain. There 
were 5 more isolates found to be resistant to Isoniazid alone and one isolate was resistant to 
Rifampicin only.  Of the 5 MDR strains, four isolates were from old cases and one was 
from a new case.
A total of 70 clinical isolates subjected for sensitivity testing by MTT assay showed 
the following results Table 4 
The  resistance  pattern  by  MTT  assay  showed  results  similar  to  the  absolute 
concentration method. The number of MDR isolates were 5 by both methods but there was 
a slight difference in the mono-resistant pattern in both the drugs. Excluding the MDR 
strains 5 and 1 isolates were  found to be resistant to Isoniazid and Rifampicin respectively 
by  absolute  concentration  method  and  the  numbers  were  4  and  2  for  Isoniazid  and 
Rifampicin  by  MTT assay.(Table  5).  The  sensitivity  of  the  MTT assay  was  90% for 
Isoniazid and 100% for Rifampicin 
The results of DNA sequencing for resistant isolates done at Macrogen.Inc showed 
mutations in the codon 526 and  codon 531(Fig 7).
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Fig 1:  Percentage of various specimens collected for the study.
BAL – bronchoalveolar lavage
Fig 2: Percentage of sputum samples in various RNTCP grades.
Fig 3: Percentage of gender distribution in the study group.
Fig 4: Age distribution among the study group
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Fig 5: Percentage of positive and negative results of the biochemical tests
Fig 6: Susceptibility pattern of the M.tuberculosis isolates in the study
MDR – Multidrug resistant, Rif – Rifampicin, INH - Isoniazid
Table 4:  Comparison of  resistance pattern  by absolute  concentration  method and MTT 
assay
COMPARISON 
OF 
SUSCEPTIBILTIY 
TESTS
Isoniazid Rifampicin
Absolute 
concentration 
method
0.2µg/mL
MTT assay
0.4µg/mL
Absolute 
concentration 
method
32µg/mL
MTT assay
2μg/mL
R S R S R S R S
10 60 9 61 6 64 7 63
TOTAL 70 70 70 70
R – resistant  S - sensitive
Table 5: Comparative evaluation of the  resistant isolates from  both susceptibilty tests
MDR – multidrug resistant , INH – Isoniazid
Drug Susceptibiltiy Test
MDR
INH
mono resistant
Rifampicin
mono resistant
Absolute concentration 
method 5 5 1
MTT assay 5 4 2
H37Rv
Rifampicin Resistant Strains
Fig 7:  The rpoB gene (81bp region) from standard strain H37Rv and Rifampicin resistant 
strains.
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               Discussion
The current global concern in the treatment of tuberculosis (TB) is the emergence of 
resistance to the two most potent drugs viz., Isoniazid and Rifampicin25
The magnitude of drug resistance prevalent in a community can have significant 
implications  for the outcome of a tuberculosis  programme,  because patients  with drug-
resistant  bacilli  respond  much  less  favourably  than  those  with  sensitive  bacilli.  Also, 
‘failure’ of treatment cases in both the groups would infect the non-infected with drug-
resistant bacilli and render treatment ineffective in them45.
During the early development of drug resistance only a small proportion of resistant 
bacteria are present within a milieu of sensitive bacteria. In a developing country like India 
with  poor  patient  compliance,  inappropriate  and/or  inadequate  treatment  leads  to 
emergence of drug resistant strains by selective multiplication of resistant  mutants within 
the lesions, in spite of the presence of growth-inhibitory concentrations of a drug46. It is 
important to monitor the level of drug resistance in the community, and adopt appropriate 
treatment regimens.
The identification of Mycobacterium to the species level plays an important role in 
providing  adequate  patient  management.  Hence  we  characterized  our  isolates  as 
M.tubeculosis complex by the following tests – Niacin production, Nitrate reduction, Heat 
stable  catalase  at  68ºC. Classical  culture and biochemical  tests,  when properly applied, 
detect  M.  tuberculosis in  clinical  samples,  with  reasonable  sensitivity47.  This  has  been 
supported by similar studies which have identification of M.tuberculosis by biochemical 
tests and molecular methods47-49. In a study by Kothadia et al50, 16% of the isolates were 
found to  be  Niacin  negative  M.tuberculosis whereas  we encountered  only 4% of  such 
isolates.
In this study 100% of the isolates were sensitive to p-nitrobenzoic acid and hence 
was  used as  a  reliable  test  along with  the  other  biochemical  tests  for  speciation.  This 
correlates well with similar studies done earlier51,52.
Though the proportion method is the gold standard for drug susceptibility testing as 
per  the  NCCLS  guidelines53,  absolute  concentration  method  was  followed  due  to  its 
technical simplicity for inoculum preparation and for reading the results46. According to 
Heifets  200054,  the  absolute  concentration  method  can  be  used  when  the  critical  drug 
concentration can be standardized in a laboratory. The Absolute concentration method was 
standardized in our laboratory with a standard MDR and sensitive strain (H37Rv) 
However  because  the  organism is  slow growing,  laboratory  diagnosis  by  these 
methods can take as along as eight to ten weeks. Rising numbers of resistant and MDR-TB 
strains have led to the pressing demand for a rapid, appropriate and accurate DST.
The MTT assay is a rapid colorimetric assay giving results in 2 weeks, compared 
with  the  conventional  absolute  concentration  method,  which  takes  4  weeks  before  the 
results can be obtained. In our study this assay showed good sensitivity for both Isoniazid 
(90%) and Rifampicin  (100%) There were high concordance levels  for Rifampicin and 
sufficiently high levels for detecting resistance for INH in our study as compared with 
other  studies  which  showed  sensitivity  of  100%  and  96%  for  Rifampicin  and  INH 
respectively37,38,43,55 
According  to  another  study,  MTT  assay  can  also  be  applied  to  direct  sputum 
samples for detection of Rifampicin resistance and when compared with agar based method 
showed a 98.5% match giving rapid results in 2 weeks56.
Resistance could be primary, i.e., infection from a source with resistant bacilli, or 
acquired due to inappropriate drug prescription, irregular drug supply to patients or non-
compliance on the part of patients. The accuracy of classification depends on the efficiency 
with which history of  previous  treatment  is  elicited  which is  often  poor  in  developing 
countries45.
A review of the few authentic reports from India57-61 indicate that there is no clear 
evidence of an increase in the prevalence of initial resistance over the years but there is a 
higher prevalence of acquired resistance reported from several regions, though based on 
smaller numbers of patients25.
In India the primary resistance to both the drugs range from 0 – 3.4% in different 
studies which is comparable to our data (1%). Our data on primary MDR –TB was also 
consistent with the global median prevalence of 1.1% (range 0 – 14.2%)62
The global resistance scenario covering 42% world’s population for acquired MDR-
TB showed a median prevalence of 7% with a range of 0 – 58.3% which places our data of 
acquired resistance (4%) well within the global range. Our study data when compared with 
the available studies in India57,63,64 and Tamil Nadu77,78,87 was lower. This may be due to our 
study representing only a proportion of patients attending the hospital.
Analysis of almost 90,000 strains between 1994 and 2002 from countries globally 
confirmed that, more strains were resistant to INH than to any other drug (0-42%)25,66.  Our 
study data showed a similar response of higher resistance to INH (10%) compared to 6% 
resistance in Rifampicin 
While  host  genetic  factors  may probably  contribute,  incomplete  and inadequate 
treatment is the most important factor leading to the development of MDR-TB5,67.
In our study group, the ratio of male to female of 3:1 was in accordance with other 
studies in India which also showed a male preponderance of 1.4-5:168,69.
Both prevalence and incidence rise with age, in both sexes. In surveys conducted so 
far in the country69 there was a preponderance of tuberculosis in the 4th and 5th decade of 
life  which  is  similar  to  our  data.  A  slight  variation  was  seen  in  a  recent  study  by 
Chakraborty ,200470 where in the peak concentration was seen at 25-34 yr age group
Rifampin (RIF) resistance serves as a surrogate marker for the detection of MDR 
TB, as 90% of Rifr isolates are also isoniazid resistant. The genetic basis for RIF resistance  
in  approximately  95%  of  the  cases  is  due  to  mutations  in  an  81-bp  RIF  resistance-
determining  region  (RRDR)  of  the  rpoB  gene,  corresponding  to  codons  507  to  533 
(Escherichia  coli  numbering  system),  which  codes  for  the  beta  subunit  of  the  RNA 
polymerase of M. tuberculosis.
Different  groups  of  workers  from  diverse  regions  of  the  world,  have  thus  far 
reported around 65 substitutions, 12 deletions, and 4 insertions in the RRDR of the rpoB 
gene.
Determination  of  the  mutation  patterns  among  large  numbers  of  isolates  from 
different parts of India is essential, for rapid detection and also identification of any hot-
spot regions in the country for proper implementation of TB control programs. . Moreover, 
it is well known that clinical isolates from southern India are very different from isolates 
from other parts of the world. It is of interest to determine whether these southern Indian 
isolates show any different kinds of mutations in the RRDR region of the rpoB gene18.
In our study, sequencing showed mutations in the commonly occurring codons 531 
(TCG to TTG) and 526 (CAC to GAC) of the rpoB gene. Previous studies have reported a 
wide range of frequencies  for mutations  at  codon 531 (20 to 71%) and codon 526 (0 to 
30%)71,72,73. Hirano et al74 has reported mutations in Indian isolates at codon 531 (TCG to 
TGG) and codon 526 (CAC to GAC).
To conclude, in our study we have detected MDR in 5% of the study group and 
mutaions were seen in commonly occurring codons. No novel mutations were encountered.
           ______________ Summary   
• The  study was taken up mainly to find out the Multi drug resistance in 
Mycobacterium tuberculosis  in this part of Tamil Nadu
• A total of 117 respiratory specimens were collected from the RNTCP outpatient 
clinic and in-patients from PSG hospitals.
• RNTCP criteria was followed for sample collection , staining and grading of 
sputum smears
• Among the samples, sputum grading ranged from scanty, 1+, 2+ and 3+
• Out of 117 specimens collected, 104 (89%) were culture positive and 3 more 
isolates were excluded from the study as they were resistant to p-nitro benzoic acid 
suggesting Non-tuberculous mycobacteria
• A total of  101 culture positive isolates were further subjected for characterization 
using biochemical tests namely Niacin production, Nitrate reduction and Heat stable 
catalase. 
• Among the study group there was male preponderance with a male to female ratio 
of 3:1
• The peak age distribution was found to be 45 – 54 years (27%)
• All the 101 isolates were found to belong to M.tuberculosis complex of which 25% 
were found to be M.bovis
• Drug susceptibility testing was done by Absolute concentration method on all the 
above isolates
• The percentage of multi-drug resistance in old cases and new cases were 4% 
(acquired resistance) and 1% (primary resistance) respectively.
• Mono-resistance to INH  was 4% in new cases and 1% in old cases whereas 
Rifampicin mono-resistance of 1%  was seen in one  new case only 
• MTT ((3-4,5-dimethylthiazol-2-yl-2,5-diphenyl tetrazolium bromide)  assay done 
for 70 isolates of M.tuberculosis from sputum samples showed a sensitivity of 90% 
and 100% for INH and Rifampicin respectively. Results of MTT assay are in 
concordance with those obtained by Absolute concentration method.
• For the six isolates (5MDR and 1 Rifampicin mono- resistant) , DNA was extracted 
by CTAB (Cetyl trimethylammonium bromide)  – Nacl method and  amplified 
(560bp) with  specific primers for rpoB  gene targeting the 81bp hotspot region 
using Eppendorf  thermocycler
• The primers used were
Forward primer 5’ GGTGGAAACCGACGACATCGA 3’
Reverse primer 5’ CGCATCGATCGGCGAATTGG 3’
•  Sequencing done for the above amplified products (Macrogen. Inc) showed 
mutations at codon 531 and codon 526
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____________________  Appendix  
Preparation of Staining Solution
1. Carbol Fuchsin
      Basic fuchsin (Hi media) 10 g
Absolute alcohol 100 ml.
Phenol    50 g.
Distilled water  900 ml.
• Weigh 5 gm of basic fuchsin dye & transfer it to a 250 ml conical flask.
• Add 50 ml of absolute alcohol & dissolve the dye by placing it in a water bath at 60º C. 
Avoid direct heating.
• Place the phenol bottle in the water bath at 80º C for melting
• Measure 50 ml of Phenol and add to the basic fuchsin solution and mix gently
• Transfer the contents into a 1L  measuring cylinder
• Add 900 ml of distilled water to make up the final volume to 1000 ml.
• Pour the solution through filter paper (Whatman No 1) and store filtered solution in a 
glass bottle. Label the bottle as 1% Carbol Fuchsin and the date of preparation.
2. 25% Sulphuric acid
Sulphuric acid, A.R.   25 ml
Distilled water             75 ml
(Note: Always add the acid to the water with mixing and never vice versa)
• Take 75 ml distilled water in a flask
• Carefully add concentrated sulphuric acid to the water 
• Mix gently and store it in an amber coloured bottle and label it as 25% sulphuric acid 
and date of preparation.
3. 0.1% Methylene Blue 
Methylene blue (BDH) - 0.5 g
Distilled water - 500 ml
• Weigh 0.5 gm of methylene blue and transfer it to a 1L conical flask
• Add 500 ml of distilled water
• Shake well & dissolve
• Store in a glass bottle with the label  as 0.1% Methylene blue and write the date  of 
preparation
4. Sodium Hydroxide Solution  4%
Sodium hydroxide Pellets, A.R. - 40 g
Distilled water - 1000 ml
• Weigh 40 gm of Sodium hydroxide and transfer to a I litre flask
• Add 1000 ml of distilled water to it and mix thoroughly until it dissolves.
• Distribute in 100 ml aliquots into 250 ml conical flasks and cover the mouth of the 
flask with cotton bunk. Wrap with aluminium foil.
• Autoclave at 15lbs/20 minutes, cool and store at 37ºC until use.
Preparation of Media
5. LOWENSTEIN JENSEN MEDIUM
Mineral Salt-Malachite green solution (SSMG)
Potassium dihydrogen orthophosphate, AR, KH2PO4 - 14.4g. 
(0.4%)
Magnesium sulphate, AR,(anhydrous)(0.4%) - 1.44 g. 
Magnesium citrate (0.1%) - 3.6 g
L-Asparagine, AR(0.6%)  - 21.6 g. 
Glycerol, AR (2%) - 72 ml   
* Malachite green 2% solution - 120 ml
Distilled water  to - 3600 ml.
*Malachite green solution 2%                         
Malachite green dye                        25g
Distilled water                                1250ml     
Homogenization of eggs
• Select fresh hens’ eggs not older than 7 days for the preparation of egg fluid.
• Cleanse eggs with soap water, place in a basin and wash in running water until the water 
is clear, then rinse in distilled water. Finally immerse in 70% alcohol for 5 minutes and 
leave to dry on a clean towel.
• Break the eggs individually into a beaker, and if fresh break the yolk with a sterile 10 ml 
pipette. Transfer the egg fluid into a 2 litre round flat-bottomed flask.
• The egg fluid is homogenized using a mechanical blender.
• Filter the egg fluid using sterile gauze and funnel
Preparation of L-J medium
• Measure out one litre of egg fluid using a sterile measuring cylinder and transfer into a 3 
or 5 litre conical flask
• 600 ml of the sterilized salt solution with malachite green (SSMG) is transferred to the 
egg fluid gently. Shake the flask to mix thoroughly.
• Distribute approximately 10 ml of medium in 1 oz. universal containers (McCartney 
bottle).
Inspissation of media
• Pour distilled water into the inspissator tank through the side opening up to the mark. 
Switch on the inspissator and check the temperature to read 85ºC
• Place the bottles in a slanted position in the inspissator, cover the slopes with a quilt and 
coagulate the medium for 50 minutes at 85ºC.
• After 50 minutes remove the bottles from the insipissator and leave at room temperature.
• The inspissator temperature is noted periodically (every 15 mts).
• Re-inspissate the bottles at 85ºC for 30 minutes on the next day.
• Label the media tray with batch number and date of preparation.
Sterility check
After inspissation, the whole media batch should be incubated at 37ºC for 24 hours. The 
media bottles are randomly checked for contamination
Preparation of reagents for biochemical tests
6. NIACIN TEST
- 4% Aniline in alcohol
Measure 0.4 ml of aniline into 9.6 ml of absolute alcohol. This solution should be prepared 
fresh just before every batch of tests and should be colourless
    -  Cyanogen bromide solution, approx. 10%.
1gm of cyanogen bromide was weighed inside the Biosafety Cabinet (BSC) and added to 
10ml of distilled water in a screw capped bottle. This solution is prepared fresh just before 
each batch of tests
7.  CATALASE TEST at 680C/pH 7.0
a. 0.067M (M/15) phosphate buffer solution, pH 7.0
              Na2HPO4, anhydrous 9.47 g
              Distilled water 1 litre
Dissolve 9.47 g of disodium phosphate in 1 litre distilled water to provide 0.067 M 
solution (Solution 1).
              KH2PO4            9.07 g
              Distilled water 1 litre
Dissolve 9.07 g of dibasic potassium phosphate in 1 litre of distilled water to give 
0.067 M KH2PO4 solution    (Solution 2)
Mix 61.1 ml of solution 1 with 38.9 ml of solution 2. Check pH.
b. Hydrogen peroxide 30% solution. 
Analytical grade H2O2 is 30%. Store in the refrigerator. 
c. Tween-80, 10%
                Tween-80 10 ml
                Distilled water 90 ml
Mix Tween-80 with distilled water and autoclave at 121oC for 10 minutes. Allow to cool. 
Store in the refrigerator.
8. Nitrate Reduction Test
(a) Substrate: 0.1M sodium nitrate
                 Sodium nitrate                                             0.85 g
      M/45 phosphate buffer, pH 7.0               100 ml
Prepare M/45 buffer by diluting M/15 buffer (as for 68oC catalase) 1:2 with distilled water. 
Dissolve the sodium nitrate in the buffer and distribute in 2-ml amounts in screw-capped 
test tubes. Sterilize at 15 lbs pressure for 15 minutes and store in the cold.
(b) Hydrochloric acid, 1:1
              Hydrochloric acid, concentrated              10 ml
              Distilled water                                          10 ml
Mix equal volumes of concentrated HCl and distilled water. Always add acid to water and 
not vice versa. Store at room temperature in a polythene bottle.
(c) Sulphanilamide, 0.2%
  Sulphanilamide                                        0.2 g
              Distilled water                                          100 ml
Dissolve 200 mg sulphanilamide in 100 ml distilled water Store in an amber colored bottle 
in the refrigerator.
(d) Coupling agent 
N- (1-naphthyl)-ethylene diamine di-HCl     0.1 g
            Distilled water                                              100 ml
Dissolve 100 mg of the coupling agent in 100 ml distilled water. Store in a dark bottle in 
the refrigerator.
(e) Zinc dust.
9. L-J MEDIUM CONTAINING  p-NITRO BENZOIC ACID (PNB)
Stock Solution
• Weigh 0.5 gm p-nitrobenzoic acid and transfer it into a concial flask containing 20 
ml of dimethyl formamide. Mix gently to dissolve the PNB.
• Transfer the entire quantity to 1 litre of L-J fluid giving a final concentration of 500 
µg/ml.
• Label the cap of the universal container as PNB
• Mix thoroughly,  distribute  approximately  10ml  volume  in  the  labeled  universal 
container and inspissate.   
Sterility check
• After inspissation, the whole media batch should be incubated at 37° C for 24 hours. 
The media bottles are randomly checked for contamination                  
10. PREPARATION OF DRUG MEDIA FOR SENSITIVITY TESTS
ISONIAZID
Stock solution
• Weigh accurately 100 mg of Isoniazid using butter paper and electronic balance.
• Transfer the weighed drug into a sterile McCartney bottle
• Add 10 ml of double sterile distilled water (DSDW) to the McCartney bottle
• Shake well to dissolve the drug completely. 
• The final concentration of the stock solution is 10,000 mg/l.
• Filter the solution using a membrane filter
Drug Susceptibility Test for 12 isolates
RIFAMPICIN (RIF)
Stock solution
• Weigh  accurately  100  mg  of  rifampicin  powder  using  butter  paper  and 
electronic balance and transfer the drug into a sterile McCartney bottle
• Add 10 ml of dimethyl formamide to the drug and shake well to dissolve.
• The final concentration of the stock solution is 10,000 mg/l. 
• The solution is self sterilizing.
Stock
(10,000 
μg/ml)
D.water Total 
(ml)
Working solution 
- concentration
Working 
solution
LJ 
( ml)
Final  conc 
in  LJ 
(μg/ml) 
 0.1 ml 4.9ml 5 ml 200 μg/ml 3ml 120 
ml
5 μg/ml
0.1 ml 24.9 ml 25 ml 40 μg/ml 3ml 120 
ml
1 μg/ml
Stock
40 
μg/ml
D.water Total 
(ml)
Working  solution 
concentration
Working 
solution
LJ ( ml) Final  conc 
in  LJ 
(μg/ml) 
1 ml 4 ml 5 ml 8 μg/ml 3 ml 120 ml 0.2 μg/ml
0.5 ml 4.5 ml 5 ml 4 μg/ml 0.6 ml 24 ml 0.1 μg/ml
0.1 ml 1.9 ml 2 ml 2 μg/ml 0.6 ml 24 ml 0.05 μg/ml
Stock
2 μg/ml
D.water Total 
(ml)
Working solution 
concentration
Working 
solution
LJ ( ml) Final  conc 
in  LJ 
(μg/ml)
0.5 ml 0.5 1 ml 1 μg/ml 0.6 24 0.025 μg/ml
Drug Susceptibility Test for 12 isolates
Distribute using pourers and inspissate once at 85oC for 50 minutes. Label the tray with the 
batch no., date of preparation and store in the cold room.
11. MTT ASSAY
Test Medium Used 
 Middle brook 7H9 broth supplemented 10% OADC and 0.01% glycerol.
Media Composition 
 Middle brook 7H9 broth base (Himedia): (pH - 6.6+/-0.2)
Composition per liter:
Na2HPO4............................................................. 2.5g
KH2PO4................................................................1.0g
Monosodium glutamate.........................................0.5g
Stock D.water Total 
(ml)
Working 
solution 
concentration
Working 
solution
LJ ( ml) Final  conc 
in  LJ 
(μg/ml)
10,000 μg/ml - - - 1.540 ml
(undiluted)
120 ml 128 μg/ml
10,000 μg/ml - - - 770μl 
(undiluted)
120 ml 64 μg/ml
 0.4 ml
(400μl)
1.6 ml 2 ml 2000 μg/ml 1.920 ml 120 ml 32 μg/ml
0.2 ml
(200 μl)
9.8 ml 10 ml 200 μg/ml 1.920 ml 24 ml 16 μg/ml
- - - “ 960 μl 24 ml 8 μg/ml
- - - “ 480 μl 24 ml 4 μg/ml
(NH4)2SO4............................................................0.5g
Sodium citrate......................................................0.1g
MgSO4·7H2O......................................................0.05g
Ferric ammonium citrate.....................................0.04g
CuSO4·5H2O.....................................................1.0mg
Pyridoxine........................................................1.0mg
ZnSO4·7H2O....................................................1.0mg
Biotin...............................................................0.5mg
CaCl2·2H2O.....................................................0.5mg
Middle brook OADC enrichment................ ….100 mL
Glycerol.............................................................2 mL 
Middle brooks OADC Enrichment (HIMEDIA):
Composition per 100.0mL:
Bovine albumin fraction V..................................5.0g
Glucose..............................................................2.0g
NaCl.................................................................0.85g
Oleic acid.........................................................0.05g
Catalase..........................................................4.0mg
Preparation of Middle brooks OADC Enrichment:
 The above mentioned components were added to distilled/deionized water and the 
volume brought upto 100mL. It was then mixed thoroughly. Filtered and sterilized.
Preparation of Medium:  Glycerol was added to 900mL of distilled/deionized water and 
the remaining media components are also added, except Middle brook OADC enrichment. 
• It was then mixed thoroughly. Gently heated and brought to boil. 
• The solution was then autoclaved at 121°C for 15 min with 15 psi pressure. It was 
cooled to 50°–55°C.
• 100mL of sterile Middle brook OADC enrichment was added aseptically and mixed 
thoroughly. 
• 4 ml was distributed into sterile tubes or flasks. The sterility checking was done on 
blood agar to rule out contamination. 
Preparation of Inoculum
• Several loopful of growth from 4 week old cultures on LJ medium were transferred 
to sterile tubes with glass beads containing 4 ml of Middle brook 7H9 broth.
• Tubes were then vortexed for five minutes to breakup larger clumps. Suspension 
was  then  allowed to  stand for  10  minutes  before  transfer  of  the  supernatant  to 
another sterile tube. 
• The supernatant  fluid  was again  allowed to  stand for  15 minutes  before  it  was 
transferred to a third sterile tube. 
• The  suspension  was  then  adjusted  to  turbidity  equivalent  to  No.1  McFarland’s 
standard using sterile saline. 
• This  standard  suspension  was  used  for  rapidly  screening  drug  susceptibility  of 
Mycobacterium tuberculosis strains using MTT assay.
Preparation of McFarland’s Standard
• 1% barium chloride was prepared by dissolving 1g of barium chloride in 100ml of 
sterile distilled water. 
• 1% sulphuric acid was prepared by dissolving 1 ml of sulphuric acid in 99 ml of 
sterile water. 
• For 0.5 McFarland’s standard, 10ml of 1% sulphuric acid was taken in a test tube 
and 0.05 ml of 1% barium chloride was added by removal of 0.05 ml of sulphuric 
acid from the tube. 
• Similarly for 1 McFarland’s standard, 10 ml of 1% sulphuric acid was taken in a 
test tube and 0.1 ml of 1% barium chloride was added by removal of 0.1 ml of 1% 
sulphuric acid from the test tube. 
Preparation of Drug Solution
Preparation of Stock Solutions & Working Concentrations
Rifampicin (Obtained from SIGMA)
Stock solutions of Rifampicin were prepared as 20 mg/mL in dimethylsulfoxoide (DMSO-
Obtained from QUALIGENS FINE CHEMICALS) and were dispensed in 0.1mL aliquots. 
They were stored at −70°C until further use. 
The  working  concentrations  were  prepared  subsequently  by  diluting  with  7H9  broth 
supplemented with OADC. 5µl of Rifampicin from stock was added to 50 ml of Middle 
brook 7H9 broth to achieve the concentration of 2µg/ml. 
Isoniazid (Obtained from SIGMA)
Stock solutions of Isoniazid were prepared 10 mg/mL in sterile distilled water (DW) and 
were dispensed in 0.1mL aliquots. They were stored at −70°C until further use. 
The  working  concentrations  were  prepared  subsequently  by  diluting  with  7H9  broth 
supplemented with OADC. 2 µl of Isoniazid from stock was added to 50 ml of Middle 
brook 7H9 broth to achieve the concentration of 0.4µg/ml. 
Preparation of MTT Solution
MTT  (3-4,  5-dimethylthiazol-2-yl-2,  5-diphenyl  tetrazolium  bromide)  obtained  from 
SIGMA. 
Contents 
MTT-5 mg
Phosphate buffer saline (PBS) - 1 ml [pH 7.2]
Procedure
• 5 mg of MTT was added to 1ml of phosphate buffered saline. 
Preparation of Phosphate Buffered Saline [pH 7.2]
Contents 
Obtained from HIMEDIA
Sodium chloride (NaCl) - 0.9 g
Potassium dihydrogen phosphate (KH2PO4) - 0.317 g
Disodium hydrogen phosphate (Na2HPO4) - 0.181 g
Distilled water- 100 ml
Procedure
• The contents were weighed and added to distilled water. 
• The pH was adjusted to 7.2 using sodium hydroxide (NaOH) 
• The solution was sterilized by autoclaving.
Preparation of 0.1 N Hcl in Isopropyl alcohol 
Contents is obtained from QUALIGENS FINE CHEMICALS 
0.1 N Hcl - 365µl 
Isopropyl alcohol – 100 ml 
Procedure 
• Hcl is added in Isopropyl alcohol and stored in tightly capped bottles.
12. Preparation of chemicals for DNA extraction 
CTAB - NaCl Method:
REAGENTS REQUIRED
• TE buffer  (pH 8)
    Stock (1M Tris, 0.5 M EDTA)
    Working (10mM Tris, 1mM EDTA)
• Lysozyme- 20 mg/ml in Milli Q water
• Sodium dodecyl sulphate-10% ( 10mg in 100ml milliQ water)
• Proteinase k- 10 mg/ml in milli Q water
• Sodium chloride (NaCl) -5M
• CTAB (Cetyl  trimethylammonium  bromide)  -NaCl  reagent  (4.1g  NaCl+  80  ml 
distilled water+ 1G CTAB-made upto 100 ml)
• Chloroform : Iso amyl alcohol (24:1)
• Isopropanol
• 70% ethanol
MATERIALS REQUIRED
• refrigerated micro-centrifuge
• 1.5 ml Eppendorf tubes
• Micropipettes (100µl to 1 ml, 5µl to 50 µl)
TBE BUFFER
• Tris (89mM)
• Boric acid (89mM)
• EDTA (2mM)
ETHIDIUM BROMIDE – 10mg/ml in distilled water.
LOADING DYE
• Bromophenol blue – trace
• Sucrose – 40mg
• Distilled water – 1ml
 Dissolve sucrose in distilled water and add a trace of bromophenol blue to it. Store the 
solution in refrigerator
_____________________  Annexure  
